[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 65 of about 65
1. Ota T, Klausen C, Salamanca MC, Woo HL, Leung PC, Auersperg N: Expression and function of HOXA genes in normal and neoplastic ovarian epithelial cells. Differentiation; 2009 Feb;77(2):162-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and function of HOXA genes in normal and neoplastic ovarian epithelial cells.
  • We studied the roles of three HOXA genes in cultured normal ovarian surface epithelial (OSE) cells and ovarian cancer cells.
  • They included HOXA4 and HOXA7 because, by cDNA microarray analysis, these were more highly expressed in invasive ovarian carcinomas than in benign or borderline (noninvasive) ovarian tumors, and HOXA9 because it characterizes normal oviductal epithelium, which resembles ovarian serous adenocarcinomas.
  • The expression of the HOXA genes varied among ovarian cancer cell lines, but was highest in lines with compact epithelial morphologies.
  • We focused on HOXA4 as the most highly expressed in the ovarian carcinoma array.
  • HOXA4 expression did not parallel proliferative activities of either OSE or ovarian cancer lines.
  • Moreover, modifying HOXA4 expression in ovarian cancer cell lines did not alter either E-cadherin expression or CA125 secretion.
  • However, HOXA4 downregulation enhanced EGFR phosphorylation and migration in serum-starved OSE and ovarian cancer cells in response to EGF, and enhanced migration of all ovarian cancer lines in 5% serum even without EGF treatment.
  • Thus, HOXA4 expression does not correlate with proliferation or with epithelial differentiation, but it increases in response to OSE cell dispersion and negatively regulates EGFR activation and the motility of OSE and of ovarian cancer cells.
  • HOXA4 expression was highest in cancer lines with compact epithelial growth patterns, suggesting, again, an anti-dispersion function.
  • In summary, increased HOXA4 expression in ovarian cancer appears to constitute a tumor-suppressive, homeostatic response to aberrant cell behavior, and, in particular, to cell dispersion and migration.
  • [MeSH-major] Epithelial Cells / metabolism. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Blotting, Western. Cell Differentiation. Cell Line, Tumor. Cells, Cultured. Down-Regulation. Female. Gene Expression Regulation. Humans. Middle Aged. Ovary / cytology. Ovary / metabolism. Reference Standards. Reverse Transcriptase Polymerase Chain Reaction


2. Fan DM, Shi HR, Chen ZM, Liu HN, Zhang RT: [Expression of TGF-beta1 and E-cadherin in primary and metastatic ovarian carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun;30(6):1355-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of TGF-beta1 and E-cadherin in primary and metastatic ovarian carcinoma].
  • OBJECTIVE: To detect the expression of the protein of TGF-beta1 and E-cadherin in the primary and metastatic lesions of ovarian carcinoma and explore the mechanism of the metastasis of ovarian carcinoma.
  • METHODS: Immunohistochemistry (IHC) was performed to detect the expression of TGF-beta1 and E-cadherin proteins in primary and metastatic ovarian carcinoma, benign epithelial ovarian tumor and normal ovarian tissue.
  • RESULTS: The expression of TGF-beta1 was significantly higher in ovarian carcinoma (67.2%) than in benign tumors (28.6%) and normal ovarian tissue (18.9%) (Chi2=26.94, P<0.001), but E-cadherin expression showed a reverse pattern.
  • TGF-beta1 expression in the primary ovarian carcinoma carcinoma was associated with the FIGO stage, lymph metastasis and ascites of the tumor (P=0.01, P=0.01, and P=0.04, respectively).
  • E-cadherin expression in the tumor was associated with the differentiation (P=0.02) and lymph metastasis of ovarian carcinoma (P=0.04).
  • The expressions of TGF-beta1 and E-cadherin were all significantly lower in the primary tumors than in the metastatic tumor (Chi2=4.70, P=0.03; Chi2=5.91, P=0.015).
  • CONCLUSION: TGF-beta1 and E-cadherin are closely associated with the metastasis of ovarian carcinoma and might be potential targets for controlling the metastasis of ovarian carcinoma.
  • [MeSH-major] Cadherins / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary. Transforming Growth Factor beta1 / metabolism
  • [MeSH-minor] Adult. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20584638.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDH1 protein, human; 0 / Cadherins; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


3. Chen LL, Ye F, Lü WG, Yu Y, Chen HZ, Xie X: Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma. J Obstet Gynaecol Res; 2009 Apr;35(2):212-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma.
  • OBJECTIVE: The aim of this study was to detect expression of different cytokines in epithelial ovarian carcinoma (EOC) cells and normal ovarian surface epithelial (OSE) cells in vitro and the levels of those with elevated expression in the EOC patients, and to analyze the contribution of cytokine profiles to tumor immune deficiency.
  • The levels of leukemia inhibitory factor (LIF), interleukin-10 (IL-10), IL-4, and transforming growth factor-beta1 (TGF-beta1) in peritoneal fluids and sera in the patients with EOC and benign gynecological tumors were detected by enzyme-linked immunosorbent assay.
  • Both LIF and IL-10 levels were more increased in ascites of EOC patients than in those in benign gynecological tumor patients (P < 0.05).
  • No difference of TGF-beta1 value was detected between patients with EOC and benign gynecological tumors.
  • CONCLUSION: Epithelium ovarian carcinoma cells can produce more LIF, IL-10 and IL-4 than OSE cells, and contribute to the elevated levels of those cytokines in EOC patients, which probably participates in the development of immune deficiency in the peritoneal cavity of EOC patients.
  • [MeSH-major] Cytokines / analysis. Neoplasms, Glandular and Epithelial / immunology. Ovarian Neoplasms / immunology
  • [MeSH-minor] Adult. Cell Line, Tumor. Female. Humans. Interleukin-10 / analysis. Interleukin-4 / analysis. Leukemia Inhibitory Factor / analysis. Transforming Growth Factor beta1 / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19335794.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cytokines; 0 / Leukemia Inhibitory Factor; 0 / Transforming Growth Factor beta1; 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4
  •  go-up   go-down


Advertisement
4. Capo-chichi CD, Yeasky TM, Heiber JF, Wang Y, Barber GN, Xu XX: Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models. Gynecol Oncol; 2010 Feb;116(2):269-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.
  • OBJECTIVE: Current treatment options for epithelial ovarian cancer are limited and therapeutic development for recurrent and drug-resistant ovarian cancer is an urgent agenda.
  • We investigated the potential use of genetically engineered Vesicular Stomatitis Virus (VSV) to treat ovarian cancer patients who fail to respond to available therapies.
  • Specifically, we examined the toxicity to hosts and specificity of targeting ovarian tumors using a Wv ovarian tumor model.
  • METHODS: We first tested recombinant VSV for oncolytic activity in a panel of human ovarian epithelial cancer, immortalized, and primary ovarian surface epithelial cells in culture.
  • Then, we tested VSV oncolytic therapy using the immune competent Wv mice that develop tubular adenomas, benign tumor lesions derived from ovarian surface epithelial cells.
  • RESULTS: The expression of GFP encoded by the recombinant VSV genome was detected in about 5% of primary ovarian surface epithelial cells (3 lines) up to 30 days without significantly altering the growth pattern of the cells, suggesting the lack of toxicity to the normal ovarian surface epithelial cells.
  • We found that regardless of the inoculation route (intra bursal, IP, or IV), VSV specifically infected and replicated in the in situ ovarian tumors in the Wv mice without significant activity in any other organs and tissues, and showed no detectable toxicity.
  • The epithelial tumor lesions were greatly reduced in VSV-targeted ovarian tumors in the Wv mice.
  • The efficient oncolytic activity of VSV for the "immortalized" non-tumorigenic ovarian surface epithelial cells suggests that the selective specificity extends from pre-neoplastic to overt cancer cells.
  • The results demonstrated the explicit targeting of ovarian epithelial tumors by VSV in immune competent, ovarian tumor-bearing mouse models, and further support the utility of VSV as an effective and safe anti-cancer agent.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • [Cites] Nat Med. 2000 Jul;6(7):821-5 [10888934.001]
  • [Cites] J Virol. 2000 Oct;74(20):9580-5 [11000229.001]
  • [Cites] J Virol. 2001 Apr;75(7):3474-9 [11238874.001]
  • [Cites] J Virol. 2002 Jan;76(2):895-904 [11752178.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3605-11 [12839948.001]
  • [Cites] J Virol. 2003 Aug;77(16):8843-56 [12885903.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4967-77 [12941822.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):51-65 [14749126.001]
  • [Cites] Trends Mol Med. 2004 May;10(5):210-6 [15121047.001]
  • [Cites] Hum Gene Ther. 2004 Sep;15(9):821-31 [15353037.001]
  • [Cites] J Natl Cancer Inst. 1972 May;48(5):1283-95 [4337905.001]
  • [Cites] J Cell Physiol. 1988 Mar;134(3):347-56 [2450877.001]
  • [Cites] Genes Dev. 1990 Mar;4(3):390-400 [1692559.001]
  • [Cites] EMBO J. 1990 Jun;9(6):1805-13 [1693331.001]
  • [Cites] Lab Invest. 1990 Jul;63(1):132-6 [2374399.001]
  • [Cites] J Virol. 2004 Dec;78(23):12747-61 [15542627.001]
  • [Cites] Viral Immunol. 2004;17(4):516-27 [15671748.001]
  • [Cites] Hepatology. 2005 Jan;41(1):196-203 [15619242.001]
  • [Cites] Cancer Gene Ther. 2005 Apr;12(4):350-8 [15565179.001]
  • [Cites] Mol Ther. 2007 Apr;15(4):651-9 [17299401.001]
  • [Cites] Am J Pathol. 2007 Apr;170(4):1325-36 [17392171.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1291-5 [18316546.001]
  • [Cites] J Mol Med (Berl). 2008 Apr;86(4):363-77 [18214411.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4506-10 [18559493.001]
  • [Cites] Semin Oncol. 2009 Apr;36(2):112-25 [19332246.001]
  • [Cites] Annu Rev Pathol. 2009;4:287-313 [18842102.001]
  • [Cites] Nat Rev Cancer. 2009 Jun;9(6):415-28 [19461667.001]
  • [Cites] Mol Cell Biol. 2009 Sep;29(17):4766-77 [19581290.001]
  • [Cites] Oncogene. 2005 Nov 21;24(52):7710-9 [16299531.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):965-76 [16294217.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):349-58 [16186807.001]
  • [Cites] Curr Opin Mol Ther. 2006 Aug;8(4):322-30 [16955695.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1546-57 [17077357.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2840-8 [17363607.001]
  • (PMID = 19932656.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083638-100010; United States / NCI NIH HHS / CA / R01 CA079716-11; United States / NCI NIH HHS / CA / CA095924-06; United States / NCI NIH HHS / CA / R01 CA099471-05; United States / NCI NIH HHS / CA / R01 CA095924-05; United States / NCI NIH HHS / CA / R01 CA79716; United States / NCI NIH HHS / CA / R01 CA099471; United States / NCI NIH HHS / CA / R01 CA75389; United States / NCI NIH HHS / CA / R01 CA079716; United States / NIAID NIH HHS / AI / R01 AI071193-01A2; United States / NIAID NIH HHS / AI / R01 AI071193; United States / NCI NIH HHS / CA / CA095924-05; United States / NCI NIH HHS / CA / CA083638-100010; United States / NCI NIH HHS / CA / CA128115-01A2; United States / NCI NIH HHS / CA / R01 CA095924-06; United States / NCI NIH HHS / CA / P01 CA128115-01A2; United States / NCI NIH HHS / CA / CA079716-11; United States / NIAID NIH HHS / AI / AI071193-01A2; United States / NCI NIH HHS / CA / P01 CA128115; United States / NCI NIH HHS / CA / P50 CA083638; United States / NIAID NIH HHS / AI / R01 AI079336; United States / NCI NIH HHS / CA / R01 CA095924; United States / NCI NIH HHS / CA / CA099471-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS161338; NLM/ PMC2813895
  •  go-up   go-down


5. Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN: Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer. Mol Carcinog; 2009 Jul;48(7):648-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer.
  • Tumor suppression as a consequence of the transfer of chromosome 3p fragments was previously observed in a novel epithelial ovarian cancer (EOC) OV-90 cell line model harboring loss of 3p.
  • Microarray analysis revealed that tumor suppression was associated with a modified transcriptome.
  • To investigate the relevance of the altered transcriptome, the differentially expressed genes identified by Affymetrix analysis in the 3p transfer studies, were integrated with a comparative microarray analysis of normal ovarian surface epithelial (NOSE) cells and malignant ovarian (TOV) cancers.
  • The investigation of these genes in benign serous ovarian tumors and EOC cell lines also exhibited predictable expression patterns.
  • Within the group of differentially expressed genes were SPARC, DAB2, CP, EVI1, ELF3, and EHD2, known to play a role in ovarian cancer, genes implicated in other cancers, such as GREM1 and GLIPR1, as well as genes not previously reported in a cancer context such as AKAP2 and ATAD4.
  • These findings suggest that the reprogramming of the transcriptome that occurred as a consequence of the chromosome 3 transfer and tumor suppression affected molecular networks that are characteristic of ovarian carcinogenesis thus validating our novel ovarian cancer cell line model.
  • [MeSH-major] Chromosomes, Human, Pair 3. Genes, Tumor Suppressor. Ovarian Neoplasms / genetics. RNA, Messenger / genetics
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction


6. Noske A, Denkert C, Schober H, Sers C, Zhumabayeva B, Weichert W, Dietel M, Wiechen K: Loss of Gelsolin expression in human ovarian carcinomas. Eur J Cancer; 2005 Feb;41(3):461-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of Gelsolin expression in human ovarian carcinomas.
  • In the present study, we analysed the expression of gelsolin in 241 matched cDNA pairs from human normal and tumour tissues using a Cancer Profiling Array.
  • We found a decreased expression of gelsolin in cancer tissue from female reproductive organs, including the ovary.
  • On a protein level, we examined the expression of gelsolin in human ovarian cancer cell lines and in a set of 110 cases of human benign and malignant ovarian tumours.
  • Low levels of gelsolin protein were observed in four of six ovarian carcinoma cell lines, in contrast to its expression in normal ovarian surface epithelial cells.
  • In addition, we found a reduced expression of gelsolin in borderline tumours and ovarian carcinomas compared with the epithelium of normal ovaries and benign adenomas.
  • In addition, we investigated the growth regulatory function of gelsolin in human ovarian cancer cell lines using cDNA transfections.
  • Re-expression of gelsolin in OAW42 and ES-2 cells resulted in a suppression of tumour cell survival in vitro.
  • To explore the mechanism responsible for the downregulation of gelsolin expression in ovarian carcinoma cells, we treated cells with inhibitors of DNA methylation and histone deacetylation.
  • We observed an upregulation of gelsolin in ovarian cancer cells after treatment with both types of inhibitor.
  • Our results suggest that gelsolin might be involved in the growth regulation of human ovarian cancer.
  • [MeSH-major] Gelsolin / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Down-Regulation. Female. Humans. Immunohistochemistry. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691647.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gelsolin
  •  go-up   go-down


7. Kline RC, Bazzett-Matabele LB: Adnexal masses and malignancies of importance to the colorectal surgeon. Clin Colon Rectal Surg; 2010 Jun;23(2):63-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this article, the authors review both benign and malignant ovarian masses, as the colorectal surgeon who encounters an adnexal mass at the time of surgery should be aware of the steps necessary for surgical staging and optimal tumor resection.Ovarian tumors-most of which are benign-are divided into three major categories, in order of frequency: epithelial, germ cell, and sex cord-stromal tumors.
  • Nonneoplastic conditions of the ovary that may present as adnexal masses include the following, according to World Health Organization (WHO) classification: pregnancy luteoma, hyperplasia of ovarian stroma, hyperthecosis, massive edema, solitary follicle cysts and corpus luteal cysts, multiple follicle cysts, and endometriosis.Epithelial ovarian tumors arise from the surface epithelium and can be benign or malignant.
  • Germ cell tumors are more likely to appear in females under 20 years, accounting for 70% of ovarian tumors in this age group.
  • The more common sex cord-stromal tumors include granulosa stromal cell tumors, Sertoli-Leydig cell tumors, and gynandroblastomas.Surgical staging and optimal tumor resection are also addressed, with a focus on epithelial malignancies, as they are the most relevant to colorectal surgeons.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):77-81 [11277654.001]
  • [Cites] JAMA. 1983 Dec 9;250(22):3072-6 [6358558.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):30-5 [16021055.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):185-91 [16216320.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):383-90 [17005244.001]
  • [Cites] Obstet Gynecol. 2009 Apr;113(4):775-82 [19305319.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(4):343-51 [2246093.001]
  • [Cites] Curr Top Pathol. 1989;78:85-109 [2651026.001]
  • [Cites] Environ Health Perspect. 1987 Aug;73:15-25 [3665859.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):139-44 [2680797.001]
  • [Cites] Obstet Gynecol. 1989 Dec;74(6):921-6 [2685680.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):983-9 [3373267.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):34-7 [12079297.001]
  • (PMID = 21629623.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2967325
  • [Keywords] NOTNLM ; Adnexal masses / ovarian cancer / ovarian cysts
  •  go-up   go-down


8. Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW, Marks JR, Berchuck A: High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer; 2006 Jul-Aug;16(4):1529-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
  • The molecular etiology of epithelial ovarian cancer remains unclear.
  • Using microarray expression analysis, we recently reported that expression of the insulin-like growth factor binding protein-2 (IGFBP-2) gene is elevated in advanced epithelial ovarian cancers.
  • The aim of this study was to further delineate the role of IGFBP-2 in the pathoetiology of epithelial ovarian cancer and determine if elevated ovarian cancer IGFBP-2 gene expression is reflected in serum.
  • Relative IGFBP-2 expression was measured using quantitative real-time polymerase chain reaction in 113 epithelial ovarian cancers and 6 normal ovarian surface epithelial samples.
  • Preoperative serum IGFBP-2 levels were measured by radioimmunoassay in 84 women (42 ovarian cancers, 26 benign gynecological conditions, and 10 healthy female controls).
  • Ovarian cancers demonstrated 38-fold higher mean IGFBP-2 expression than normal ovarian epithelium (P < 0.01).
  • Serum IGFBP-2 levels were elevated in women with early- and advanced-stage ovarian cancer compared to controls and patients with benign gynecological conditions (P = 0.05 and P < 0.01, respectively).
  • Epithelial ovarian cancers express high levels of IGFBP-2 relative to normal ovarian epithelium, and this is associated with elevated serum IGFBP-2 levels compared to both normal controls and patients with benign gynecological disease.
  • Our findings provide further support that the insulin-like growth factor pathway plays a significant role in epithelial ovarian cancer pathogenesis.
  • Further, IGFBP-2 may represent an additional serum biomarker with utility in detection and monitoring of epithelial ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Gene Expression Regulation, Neoplastic / genetics. Insulin-Like Growth Factor Binding Protein 2 / blood. Neoplasms, Glandular and Epithelial / blood. Ovarian Neoplasms / blood. RNA, Messenger / blood
  • [MeSH-minor] Adenocarcinoma, Clear Cell / blood. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / surgery. CA-125 Antigen / blood. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / surgery. Endometrial Neoplasms / blood. Endometrial Neoplasms / genetics. Endometrial Neoplasms / surgery. Female. Humans. Immunoenzyme Techniques. Neoplasm Staging. Ovarian Cysts / blood. Ovarian Cysts / genetics. Ovary / pathology. Precancerous Conditions / blood. Precancerous Conditions / genetics. Precancerous Conditions / surgery. Preoperative Care. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16884361.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / RNA, Messenger
  •  go-up   go-down


9. Yoshida J, Horiuchi A, Kikuchi N, Hayashi A, Osada R, Ohira S, Shiozawa T, Konishi I: Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression. Med Mol Morphol; 2009 Jun;42(2):82-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression.
  • Changes in the expression of E-cadherin have been reported to be important in the tumorigenesis and progression of epithelial ovarian carcinoma.
  • To further examine the mechanisms regulating E-cadherin expression in ovarian tumorigenesis, we investigated the immunohistochemical expression of transcriptional repressors for E-cadherin, such as Snail, Slug, SIP1, and Twist, in the ovarian surface epithelium (OSE) and 95 cases of epithelial ovarian tumors.
  • Of 95 ovarian tumors, the expression of Snail, Slug, SIP1, and Twist increased stepwise in benign, borderline, and malignant tumors.
  • The prognosis of ovarian carcinoma patients positive for Snail expression was poorer than that of negative patients.
  • Our results indicate that the expression of E-cadherin transcriptional repressors increased with malignancy in ovarian epithelial neoplasms and that the expression of E-cadherin and its negative regulators is altered during ovarian cancer development and peritoneal dissemination.
  • [MeSH-major] Cadherins / metabolism. Carcinoma / metabolism. Ovarian Neoplasms / metabolism. Repressor Proteins / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Blotting, Western. Disease Progression. Female. Humans. Immunohistochemistry. Nerve Tissue Proteins / analysis. Nerve Tissue Proteins / metabolism. Nuclear Proteins / analysis. Nuclear Proteins / metabolism. Ovary / chemistry. Ovary / cytology. Ovary / pathology. RNA-Binding Proteins / analysis. RNA-Binding Proteins / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Snail Family Transcription Factors. Twist-Related Protein 1 / analysis. Twist-Related Protein 1 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1437-47 [14507651.001]
  • [Cites] Hum Pathol. 1997 Aug;28(8):922-8 [9269828.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12 (18):5369-76 [17000670.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):24661-6 [11323412.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1469-76 [15619205.001]
  • [Cites] J Surg Res. 2007 Aug;141(2):196-203 [17583745.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):180-8 [10188716.001]
  • [Cites] J Pathol. 2000 Dec;192(4):460-9 [11113863.001]
  • [Cites] Br J Cancer. 2002 Jan 7;86(1):98-101 [11857019.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):16-7 [10973239.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12 ):1816-22 [16773075.001]
  • [Cites] Lancet Oncol. 2006 Nov;7(11):925-34 [17081918.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3241-6 [12082640.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Mar;21(1):65-71 [12071532.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):155-65 [15790452.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):520-8 [17024425.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):314-20 [17211477.001]
  • [Cites] Clin Exp Metastasis. 2006;23(1):65-74 [16826427.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):155-66 [11994736.001]
  • [Cites] Biol Rev Camb Philos Soc. 1996 Nov;71(4):529-43 [8923798.001]
  • [Cites] J Pathol. 1998 Jul;185(3):262-6 [9771479.001]
  • [Cites] Histopathology. 1998 Jan;32(1):69-80 [9522220.001]
  • [Cites] Curr Opin Oncol. 1994 Jan;6(1):106-13 [7515692.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6249-54 [10339573.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Cell Cycle. 2006 Aug;5(16):1756-9 [16880738.001]
  • [Cites] Clin Exp Metastasis. 2007;24(5):329-39 [17487558.001]
  • (PMID = 19536615.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / GEMIN2 protein, human; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / RNA-Binding Proteins; 0 / Repressor Proteins; 0 / SNAI1 protein, human; 0 / Snail Family Transcription Factors; 0 / TWIST1 protein, human; 0 / Transcription Factors; 0 / Twist-Related Protein 1
  •  go-up   go-down


10. Zhang SL, Yu Y, Jiang T, Lin B, Gao H: [Expression and significance of KiSS-1 and its receptor GPR54 mRNA in epithelial ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi; 2005 Oct;40(10):689-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of KiSS-1 and its receptor GPR54 mRNA in epithelial ovarian cancer].
  • OBJECTIVE: To study the expression and significance of metastasis suppressor gene KiSS-1 and its receptor GPR54 in epithelial ovarian cancer.
  • METHOD: The expression and their clinical significance of KiSS-1 and GPR54 were evaluated by RT-PCR in 37 patients with epithelial ovarian cancer, 15 patients with borderline epithelial ovarian tumors, 15 patients with epithelial benign tumors and 11 patients with normal ovarian tissues.
  • RESULTS: The positivity and relative contents of KiSS-1 mRNA in patients with epithelial ovarian cancer (68%, 0.82 +/- 0.09) and borderline epithelial ovarian tumors (60%, 0.80 +/- 0.10) were all higher than in patients with epithelial benign tumor (20%, 0.65 +/- 0.10) and normal ovarian tissues (18%, 0.66 +/- 0.06; P < 0.05).
  • The positivity and relative contents of KiSS-1 mRNA in patients with epithelial ovarian cancer correlated with their clinical stage and lymph node metastasis (P < 0.05).
  • There was no difference in the positivity and relative contents of GPR54 mRNA between patients with epithelial ovarian cancer (70%, 0.79 +/- 0.07), borderline epithelial ovarian tumor (67%, 0.76 +/- 0.10), benign epithelial ovarian tumor (60%, 0.73 +/- 0.07) and normal ovarian tissues (45%, 0.78 +/- 0.08), respectively (all P > 0.05).
  • The positivity and relative contents of GPR54 mRNA in patients with epithelial ovarian cancer did not correlate with their clinical stage, histology grade, lymph node metastasis and production of ascites (P > 0.05).
  • CONCLUSION: KiSS-1 and GPR54 may play an important role in inhibiting the invasion and metastasis of early epithelial ovarian cancer.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / pathology. Receptors, G-Protein-Coupled / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Kisspeptins. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277902.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / KISS1 protein, human; 0 / KISS1R protein, human; 0 / Kisspeptins; 0 / RNA, Messenger; 0 / Receptors, G-Protein-Coupled; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


11. Leung YK, Lau KM, Mobley J, Jiang Z, Ho SM: Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res; 2005 May 1;65(9):3726-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis.
  • Epithelial ovarian cancer derived from the human ovarian surface epithelium (HOSE) is the leading cause of death from gynecologic malignancies among American women.
  • In this study, we showed overexpression of CYP1A1 mRNA, but not CYP1B1 transcripts, in ovarian cancer cell lines when compared with primary cultures or immortalized HOSE cell lines.
  • CYP1A1v is overexpressed in ovarian cancer cell lines and exhibits a unique subcellular distribution restricted to the nucleus and mitochondria, contrary to the endoplasmic reticulum localization of the wild-type enzyme.
  • In concordance, total CYP1A1 activity, as measured by the ethoxyresorufin O-deethylase assay, was detected in mitochondrial, nuclear, and microsomal fractions of ovarian cancer cells but was notably absent in all subcellular fractions of HOSE cells.
  • Immunocytochemistry studies in 30 clinical specimens revealed overexpression of CYP1A1 in various types of ovarian cancers compared with benign epithelia and frequent localization of the enzyme to cancer cell nuclei.
  • Collectively, these data provided the first evidence that CYP1A1 overexpression and alternative splicing could contribute to ovarian cancer initiation and progression.
  • [MeSH-major] Cytochrome P-450 CYP1A1 / biosynthesis. Cytochrome P-450 CYP1A1 / genetics. Ovarian Neoplasms / enzymology. Ovarian Neoplasms / genetics
  • [MeSH-minor] Alternative Splicing. Base Sequence. Benzo(a)pyrene / pharmacokinetics. Carcinogens / pharmacokinetics. Cell Line, Tumor. Cell Nucleus / enzymology. Cell Transformation, Neoplastic / drug effects. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Epithelium / enzymology. Epithelium / pathology. Estradiol / pharmacokinetics. Female. Humans. Isoenzymes. Mitochondria / enzymology. Molecular Sequence Data. Ovary / cytology. Ovary / drug effects. Ovary / enzymology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Subcellular Fractions / enzymology. Transfection

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867368.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA94221
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Isoenzymes; 0 / RNA, Messenger; 3417WMA06D / Benzo(a)pyrene; 4TI98Z838E / Estradiol; EC 1.14.14.1 / Cytochrome P-450 CYP1A1
  •  go-up   go-down


12. Abd El-Wahed MM: Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features. J Egypt Natl Canc Inst; 2005 Sep;17(3):173-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features.
  • BACKGROUND AND PURPOSE: Maspin is an inhibitor of serine proteinases with tumor suppressor activity that is down-regulated in breast and prostate cancer, but overexpressed in pancreatic carcinoma.
  • However, there were very few published data regarding the role of maspin in ovarian carcinoma.
  • The aim of the present study was to evaluate maspin expression in ovarian epithelial neoplasms and correlate its expression with some clinicopathologic parameters.
  • MATERIAL AND METHODS: Seventy eight paraffin embedded ovarian specimens from patients with ovarian epithelial neoplasms comprised the material of this study.
  • They included 18 benign, 14 low malignant potential (LMP) and 46 malignant epithelial ovarian neoplasms, in addition to seven specimens from normal ovarian tissues as a control.
  • RESULTS: Immunohistochemical study of maspin expression using streptavidin biotin immunoperoxidase method revealed that, normal ovarian surface epithelium did not express maspin as well as benign serous and mucinous ovarian epithelial neoplasm.
  • However, all benign Brenner ovarian tumors were maspin positive.
  • On the other hand, 57.14% of LMP tumors showed weak maspin expression and 63% of malignant ovarian epithelial tumors showed maspin expression with 39.1% over expression.
  • CONCLUSION: Maspin was expressed in a substantial proportion of ovarian tumors with poor prognostic parameters.
  • These results may offer new insights regarding the role of maspin in ovarian cancer that may also impact diagnosis and treatment strategies.
  • Moreover, variation in maspin expression between Brenner tumor and other epithelial surface ovarian tumors may indicate that the different histological types probably represent distinct disease entities and involve different molecular pathways.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Serine Proteinase Inhibitors / metabolism
  • [MeSH-minor] Adolescent. Adult. Brenner Tumor / metabolism. Brenner Tumor / pathology. CA-125 Antigen / analysis. Carcinoembryonic Antigen / analysis. Epithelium / metabolism. Female. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Middle Aged. Ovary / metabolism. Serpins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799655.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / SERPIN-B5; 0 / Serine Proteinase Inhibitors; 0 / Serpins
  •  go-up   go-down


13. Bazzaro M, Lee MK, Zoso A, Stirling WL, Santillan A, Shih IeM, Roden RB: Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res; 2006 Apr 1;66(7):3754-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
  • Herein, we show that ovarian carcinoma manifests an overstressed UPS by comparison with normal tissues by accumulation of ubiquitinated proteins despite elevated proteasome levels.
  • Elevated levels of total ubiquitinated proteins and 19S and 20S proteasome subunits are evident in both low-grade and high-grade ovarian carcinoma tissues relative to benign ovarian tumors and in ovarian carcinoma cell lines relative to immortalized surface epithelium.
  • We find that ovarian carcinoma cell lines exhibit greater sensitivity to apoptosis in response to proteasome inhibitors than immortalized ovarian surface epithelial cells.
  • Furthermore, treatment with the licensed proteasome inhibitor PS-341 slows the growth of ES-2 ovarian carcinoma xenograft in immunodeficient mice.
  • In sum, elevated proliferation and metabolic rate resulting from malignant transformation of the epithelium stresses the UPS and renders ovarian carcinoma more sensitive to apoptosis in response to proteasomal inhibition.
  • [MeSH-major] Apoptosis / drug effects. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism. Protease Inhibitors / pharmacology. Proteasome Endopeptidase Complex / metabolism. Proteasome Inhibitors. Ubiquitin / metabolism
  • [MeSH-minor] Animals. Boronic Acids / pharmacology. Bortezomib. Caspases / metabolism. Cell Division / drug effects. Cell Line, Tumor. Female. G2 Phase / drug effects. Humans. Leupeptins / pharmacology. Mice. Mice, Nude. Oligopeptides / pharmacology. Pyrazines / pharmacology. Xenograft Model Antitumor Assays


14. Shi HR, Zhang RT: [Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer]. Ai Zheng; 2009 Aug;28(8):882-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer].
  • This study was to investigate the expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer.
  • METHODS: The expression of P53, P21WAF1 and CDK1 proteins in 20 specimens of normal ovarian tissues, 20 specimens of benign epithelial ovarian tumor and 76 specimens of epithelial ovarian cancer was detected by immunohistochemistry.
  • Their correlations to the clinicopathologic characteristics of epithelial ovarian cancer and their interrelationships were analyzed.
  • RESULTS: Significant differences were noted in the positive rates of P53, P21WAF1 and CDK1 proteins between epithelial ovarian cancer and normal ovarian tissues, benign ovarian tumors (P < 0.05).
  • In epithelial ovarian cancer, up-regulation of P53 protein was associated with advanced FIGO stage and poor differentiation; down-regulation of P21WAF1 protein was associated with advanced FIGO stage; CDK1 showed no association with any clinicopathologic factors.
  • CONCLUSIONS: P53 protein is related to the malignancy of epithelial ovarian cancer, P53 and P21WAF1 protein may be related to the malignant development of epithelial ovarian cancer.
  • CDK1 detection may be helpful in the early diagnosis of epithelial ovarian cancer.
  • [MeSH-major] CDC2 Protein Kinase / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Ovarian Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664338.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.11.22 / CDC2 Protein Kinase
  •  go-up   go-down


15. Reed J, Hakam A, Nicosia SV, Coppola D: Significance of Fas receptor protein expression in epithelial ovarian cancer. Hum Pathol; 2005 Sep;36(9):971-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of Fas receptor protein expression in epithelial ovarian cancer.
  • Fas receptor (FasR) is a cell surface receptor that, when activated, triggers apoptosis.
  • It has been postulated that this receptor may be involved in the clearance of benign ovarian epithelial inclusion cysts (IC).
  • The stain was semiquantitatively scored by 3 observers evaluating the intensity of the stain and percentage of positive tumor cells.
  • The decreased expression of FasR in malignant ovarian epithelial neoplasms as compared with benign ovarian epithelial lesions suggests that a decreased sensitivity to Fas-mediated apoptosis may be involved in ovarian epithelial carcinogenesis.
  • [MeSH-major] Antigens, CD95 / metabolism. Cystadenocarcinoma, Papillary / metabolism. Cystadenoma, Serous / metabolism. Membrane Glycoproteins / metabolism. Ovarian Neoplasms / metabolism


16. Huddleston HG, Wong KK, Welch WR, Berkowitz RS, Mok SC: Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol; 2005 Jan;96(1):77-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker.
  • OBJECTIVE:. (1) To identify and (2) validate genes that are up-regulated in ovarian cancer, and (3) to investigate whether the activity of a candidate gene, creatine kinase B (CKB) is elevated in pre-operative sera from ovarian cancer patients compared to patients with benign pelvic masses and normal controls.
  • METHODS: MICROMAX cDNA microarray system and RNA derived from pooled ovarian cancer cell lines and normal ovary surface epithelial cells (HOSE) were used to identify differentially expressed genes.
  • Using a commercially available enzyme assay, CKB activity was measured in pre-operative serum samples obtained from 45 ovarian cancer patients, 49 patients with a benign pelvic mass, as well as 37 normal controls.
  • RNA levels of CKB, measured by real-time PCR, were elevated a mean (and standard error) of 36-fold (8.4) in cancer cell lines compared with HOSE cells and 22.75-fold (10.45) in microdissected ovarian cancer epithelial cells compared with normal ovarian epithelial cells.
  • In serum, the mean (+/-standard error) of CKB enzyme activity in cancer cases was 24.7 U/L units (+/- 5.1) compared to 9.6 U/L (+/- 1.6) for benign mass cases (P = 0.0088) and to 8.5 U/L (1.7) for normal controls (P = 0.0096).
  • CONCLUSIONS: Microarray technology offers a method to identify tumor biomarkers with potential clinical usefulness.
  • Our data indicated that CKB gene expression is up-regulated in ovarian cancer cells in vitro and in vivo and that CKB enzyme activity is significantly elevated in sera from ovarian cancer patients, including those with stage I disease.
  • These findings suggest a potential role for CKB as a marker for early diagnosis.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Creatine Kinase / biosynthesis. Isoenzymes / biosynthesis. Oligonucleotide Array Sequence Analysis / methods. Ovarian Neoplasms / enzymology
  • [MeSH-minor] Adult. Creatine Kinase, BB Form. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589584.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA86381; United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / RNA, Neoplasm; EC 2.7.3.2 / Creatine Kinase; EC 2.7.3.2 / Creatine Kinase, BB Form
  •  go-up   go-down


17. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL: Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res; 2005 Mar 15;65(6):2162-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.
  • Among the genes most commonly identified in gene expression profiles of epithelial ovarian carcinomas (EOC) is the gene for human epididymis protein 4 (HE4).
  • To ascertain its clinical utility, we did a comprehensive assessment of HE4 protein expression in benign and malignant ovarian and nonovarian tissues by immunohistochemistry.
  • In comparison with normal surface epithelium, which does not express HE4, we found that cortical inclusion cysts lined by metaplastic Mullerian epithelium abundantly express the protein.
  • Using reverse transcription-PCR, we identified ovarian cancer cell lines that endogenously overexpress HE4.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Serous / metabolism. Epididymal Secretory Proteins / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Cell Line, Tumor. Epithelium / metabolism. Female. Humans. Mullerian Ducts / metabolism. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. beta-Defensins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781627.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / RNA, Messenger; 0 / beta-Defensins
  •  go-up   go-down


18. Jha R, Karki S: Histological pattern of ovarian tumors and their age distribution. Nepal Med Coll J; 2008 Jun;10(2):81-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological pattern of ovarian tumors and their age distribution.
  • A female's risk at birth of having ovarian tumor sometime in her life is 6-7%.
  • Relative frequency of ovarian tumor is different for western and Asian countries.
  • Two third of ovarian tumors occur in women of reproductive age group.
  • This study was done in Tribhuvan University Teaching Hospital with aim to find out frequency of different histological types of ovarian tumors and their age distribution and thus provide an institutional experience from Nepal also.
  • One hundred and sixty one ovarian tumors, reported from April 2004 to March 2006 were included in the study.
  • One hundred and thirty five of these tumors (83.9%) were benign and 16.1% (26/161) were malignant.
  • Surface epithelial tumors were most common (52.2%) followed by germ cell tumors (42.2%).
  • Mature cystic teratoma was commonest benign tumor (48.2%).
  • Serous adenocarcinoma was commonest malignant tumor (46.2%).
  • For all age groups, benign tumors were more common than malignant ones.
  • Most ovarian tumors (47.2%) were seen between 21 -40 years where as most malignant tumors (73.1%) were seen above 40 years.
  • [MeSH-major] Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18828427.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


19. Noske A, Weichert W, Niesporek S, Röske A, Buckendahl AC, Koch I, Sehouli J, Dietel M, Denkert C: Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer; 2008 Apr 15;112(8):1733-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer.
  • Whereas cell-biologic studies have suggested a fundamental role for CRM1 in the regulation of mitosis, the expression of this protein in human tumor tissue has not been investigated to date.
  • METHODS: In this study, the expression of CRM1 was analyzed in a cohort of 88 ovarian tumors and 12 ovarian cell lines for the first time to the authors' knowledge.
  • RESULTS: Immunohistochemistry revealed increased nuclear (52.7%) and cytoplasmic (56.8%) expression of CRM1 in 74 carcinomas compared with the expression revealed in borderline tumors and benign lesions.
  • Similarly, CRM1 expression was increased in ovarian cancer cell lines compared with human ovarian surface epithelial cells.
  • Cytoplasmic CRM1 expression was related significantly to advanced tumor stage (P= .043), poorly differentiated carcinomas (P= .011), and higher mitotic rate (P= .008).
  • CONCLUSIONS: The current results indicated that CRM1 is expressed in a subpopulation of ovarian carcinomas with aggressive behavior and is related to poor patient outcome.
  • A correlation also was demonstrated between CRM1 and COX-2 expression in ovarian cancer tissue.
  • Furthermore, the treatment of ovarian cancer cells with LMB revealed a reduction in COX-2 expression.
  • [MeSH-major] Karyopherins / analysis. Ovarian Neoplasms / pathology. Receptors, Cytoplasmic and Nuclear / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / therapeutic use. Apoptosis / drug effects. Carcinoma / pathology. Cell Line, Tumor. Cell Nucleus / ultrastructure. Cell Proliferation / drug effects. Cohort Studies. Cyclooxygenase 2 / analysis. Cytoplasm / ultrastructure. Epithelial Cells / pathology. Fatty Acids, Unsaturated / therapeutic use. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Interleukin-1beta / drug effects. Middle Aged. Mitosis / genetics. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306389.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Fatty Acids, Unsaturated; 0 / Interleukin-1beta; 0 / Karyopherins; 0 / Receptors, Cytoplasmic and Nuclear; 0 / exportin 1 protein; 87081-35-4 / leptomycin B; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


20. Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF: Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother; 2009 Sep;58(9):1375-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toll-like receptor expression in normal ovary and ovarian tumors.
  • Recent studies have implicated inflammation in the initiation and progression of ovarian cancer, though the mechanisms underlying this effect are still not clear.
  • Tumor cell expression of TLRs can promote inflammation and cell survival in the tumor microenvironment.
  • Here we sought to characterize the expression of TLRs in normal human ovaries, benign and malignant ovarian tumors from patients, and in established ovarian tumor cell lines.
  • We report that TLR2, TLR3, TLR4, and TLR5 are strongly expressed on the surface epithelium of normal ovaries.
  • TLR2, TLR3, TLR4, and TLR5 are expressed in benign conditions, epithelial tumors, and in ovarian cancer cell lines.
  • Variable expression of TLR6 and TLR8 was seen in benign and malignant epithelium of some patients, while expression of TLR1, TLR7, and TLR9 was weak.
  • Normal and malignant ovarian stroma were negative for TLR expression.
  • These studies demonstrate expression of multiple TLRs in the epithelium of normal ovaries and in ovarian tumor cells, and may indicate a mechanism by which epithelial tumors manipulate inflammatory pathways to facilitate tumor progression.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Cystadenocarcinoma, Serous / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism. Toll-Like Receptors / metabolism
  • [MeSH-minor] Adult. Aged. Animals. Epithelial Cells / metabolism. Estrous Cycle / metabolism. Female. Humans. Immunoenzyme Techniques. Mice. Mice, Inbred C57BL. Middle Aged. Prognosis. Tissue Array Analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19184006.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Toll-Like Receptors
  •  go-up   go-down


21. Petri AL, Simonsen AH, Yip TT, Hogdall E, Fung ET, Lundvall L, Hogdall C: Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet Gynecol Scand; 2009;88(1):18-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.
  • OBJECTIVE: To examine whether urine can be used to measure specific ovarian cancer proteomic profiles and whether one peak alone or in combination with other peaks or CA125 has the sensitivity and specificity to discriminate between ovarian cancer pelvic mass and benign pelvic mass.
  • Of the women, 156 had benign gynaecological tumors, 13 had borderline tumors and 40 had malignant epithelial ovarian cancer.
  • The urine was fractionated using equalizer bead technology and then analyzed with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
  • RESULTS: Benign and malignant ovarian cancer cases were compared; 21 significantly different peaks (p<0.001) were visualized using Mann-Whitney analysis, ranging in m/z values from 1,500 to 185,000.
  • [MeSH-major] Biomarkers, Tumor / metabolism. CA-125 Antigen / analysis. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Biopsy, Needle. Disease Progression. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Immunohistochemistry. Laparotomy / methods. Middle Aged. Neoplasm Staging. Pelvic Neoplasms / blood. Pelvic Neoplasms / pathology. Pelvic Neoplasms / surgery. Pelvic Neoplasms / urine. Predictive Value of Tests. Probability. Prognosis. Prospective Studies. Proteomics. ROC Curve. Risk Assessment. Sampling Studies. Sensitivity and Specificity. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19023702.001).
  • [ISSN] 1600-0412
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


22. Esheba GE, Pate LL, Longacre TA: Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am J Surg Pathol; 2008 Apr;32(4):600-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
  • Clear cell carcinoma (CCC) of the ovary is the surface epithelial neoplasm most often confused with primitive germ cell tumors, particularly yolk sac tumor (YST) and dysgerminoma.
  • To investigate whether GPC3 is useful in distinguishing YST from ovarian CCC, we studied the expression of GPC3 in a large series of ovarian neoplasms and compared it to the expression profiles of CK7 and alpha-fetoprotein.
  • Tissue microarrays containing over 400 benign and malignant ovarian neoplasms, including 34 CCCs were stained with monoclonal GPC3 (clone 1G12, Biomosaics, Burlington, VT).
  • These arrays contained a wide assortment of ovarian surface epithelial neoplasms and sex cord stromal neoplasms, as well as germ cell tumors.
  • All but one YST (97%), including those associated with mixed germ cell tumor were positive for GPC3, whereas all teratomas and embryonal carcinomas were negative.
  • All other tissues, including normal ovary were negative for GPC3.
  • GPC3 seems to be a promising diagnostic marker for differentiating YST from ovarian CCC (P < 0.0001).
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoma / chemistry. Endodermal Sinus Tumor / chemistry. Glypicans / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7 / analysis. Predictive Value of Tests. Sensitivity and Specificity. Tissue Array Analysis. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277882.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPC3 protein, human; 0 / Glypicans; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / alpha-Fetoproteins; 0 / oncofetal antigens
  •  go-up   go-down


23. Rajesh NG, Rekha K, Krishna B: Significance of p53 expression in ovarian tumors and its correlation to the morphological differentiation. Indian J Pathol Microbiol; 2007 Apr;50(2):284-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of p53 expression in ovarian tumors and its correlation to the morphological differentiation.
  • Interestingly the ovarian cancer has the highest mortality rate.
  • This is attributed to its late clinical presentation and delayed diagnosis.
  • The expression of p53 throws light on the prognosis of ovarian tumors.
  • The surface epithelial tumors, especially the serous cystadenocarcinoma and non Hodgkin lymphoma of ovary where in the expression p53 was high compared to the benign and borderline tumors.
  • Further the expression of p53 in tumors arising from germinal cells, sex-cord stromal cells are observed to be very low.
  • [MeSH-major] Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883046.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


24. Zhu Y, Brännström M, Janson PO, Sundfeldt K: Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int J Cancer; 2006 Apr 15;118(8):1884-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours.
  • Human ovarian surface epithelium (OSE), regarded as the precursor cell of epithelial ovarian adenocarcinoma, is not a fully developed epithelium when situated on the ovarian surface.
  • It lacks epithelial characteristics such as the cell-cell adhesion factor epithelial (E)-cadherin, but as we have shown earlier, this OSE can form functional tight junctions (TJs) in culture.
  • Recent gene-expression data on ovarian adenocarcinoma has pointed out a family of TJ proteins, the claudins, to be highly expressed in malignant compared to benign ovarian tumours.
  • The purpose of this study was to investigate the distribution of claudin 1-5 proteins in cultured OSE (n=4), normal ovarian (n=11), benign (n=8), borderline (n=7) and ovarian cancer (n=22) tissues.
  • We found that a weak or absence of expression of claudin 3 and claudin 4 in surface OSE changed to typical cell-border localisation in OSE of inclusion cysts in the normal ovarian stroma.
  • Semiquantitative estimations of immunoblots showed that claudin 3 was significantly increased in ovarian adenocarcinomas compared to benign and borderline-type tumours.
  • Claudin 4 was significantly increased in both borderline-type and ovarian adenocarcinomas compared to benign tumours, whereas no changes were found for claudin 1 or 5.
  • We conclude that both claudin 3 and 4, even though they differ in expression during ovarian malignant transformation, might be used as novel markers for ovarian tumours.
  • [MeSH-major] Adenocarcinoma / genetics. Membrane Proteins / biosynthesis. Ovarian Cysts / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Claudin-1. Claudin-3. Claudin-4. Claudin-5. Epithelium. Female. Gene Expression Profiling. Humans. Immunoblotting. Ovary / physiology. Phenotype. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16287068.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN5 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudin-5; 0 / Membrane Proteins
  •  go-up   go-down


25. Hart WR: Borderline epithelial tumors of the ovary. Mod Pathol; 2005 Feb;18 Suppl 2:S33-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Borderline epithelial tumors of the ovary.
  • The concept and terminology of borderline epithelial tumors of the ovary have been controversial for over a century, in spite of the acceptance of a borderline category in almost all current classifications of ovarian tumors.
  • Typically, borderline tumors are noninvasive neoplasms that have nuclear abnormalities and mitotic activity intermediate between benign and malignant tumors of similar cell type.
  • Borderline tumors of all surface epithelial cell types have been studied.
  • Some of the most challenging issues for serous tumors include: the criteria and clinical behavior of stromal microinvasion; the high prevalence of synchronous extraovarian disease; the classification and histopathologic features of associated peritoneal tumor implants, especially invasive implants; and, the prognostic significance of micropapillary tumors.
  • The mucinous borderline tumors of intestinal type have a different set of considerations, including: their frequently heterogeneous composition with coexisting benign, borderline and malignant elements; the classification and significance of accompanying noninvasive carcinoma; the recognition of stromal invasion, including microinvasion and expansile invasion; and, the historically misunderstood relationship to pseudomyxoma peritonei.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761465.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 93
  •  go-up   go-down


26. Kinkor Z, Michal M: [Syndrome of pseudomyxoma peritonei--description of three cases and survey of the problem]. Ceska Gynekol; 2005 Jan;70(1):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Pseudomyxoma peritonei is a clinical syndrome defined as presence of massive mucinous, viscous material in the peritoneal cavity, both floating and adhering to serosal surface (jelly-belly).
  • The histologic examination should always follow with detailed and precise description of the epithelial component.
  • First and more frequent, so-called disseminated peritoneal adenomucinosis, where primary low grade (benign) mucinous appendiceal tumor is almost constant finding, often recurs but displays favorable prognosis.
  • Histopathogenesis in both types is thought to arise from MUC2 positive goblet cells in GI and ovarian involvement is secondary.

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15779299.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


27. Rosen DG, Yang G, Bast RC Jr, Liu J: Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. Methods Enzymol; 2006;407:660-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer.
  • The Ras gene family has been implicated in the development of many human epithelial cancers.
  • Mutations in K-ras or its downstream mediator BRAF have been detected in about two thirds of low-grade serous carcinomas and borderline serous tumors; mutations in K-ras are also often present in benign and invasive mucinous ovarian cancers.
  • Although the oncogenic allele H-ras(V12) is present in only approximately 6% of ovarian cancers, physiologically activated H-ras protein is commonly detected in human ovarian cancer, presumably because of an increase in upstream signals from tyrosine kinase growth factor receptors such as Her-2/neu, despite the lack of a Ras mutation.
  • The mechanisms by which ras oncogenes transform human epithelial cells are not clear.
  • The methods described here are what we use to culture human ovarian surface epithelial cells, to immortalize those cells, and to transform the immortalized cells with oncogenic H-ras or K-ras.
  • These Ras-transformed human ovarian surface epithelial cells form tumors in nude mice and recapitulate many features of human ovarian cancer, thus providing an excellent model system for studying the initiation and progression of human ovarian cancer.
  • [MeSH-major] Cell Transformation, Neoplastic. Oncogene Protein p21(ras) / pharmacology. Ovarian Neoplasms / physiopathology. Ovary / cytology
  • [MeSH-minor] Animals. Antigens, Viral, Tumor / pharmacology. Cells, Cultured. Epithelial Cells / drug effects. Female. Humans. Immunohistochemistry. Mice. Mice, Nude. Simian virus 40 / immunology. Telomerase / pharmacology. Transfection


28. Redjimi N, Gaudin F, Touboul C, Emilie D, Pallardy M, Biola-Vidamment A, Fernandez H, Prévot S, Balabanian K, Machelon V: Identification of glucocorticoid-induced leucine zipper as a key regulator of tumor cell proliferation in epithelial ovarian cancer. Mol Cancer; 2009;8:83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of glucocorticoid-induced leucine zipper as a key regulator of tumor cell proliferation in epithelial ovarian cancer.
  • BACKGROUND: Little is known about the molecules that contribute to tumor progression of epithelial ovarian cancer (EOC), currently a leading cause of mortality from gynecological malignancies.
  • Glucocorticoid-Induced Leucine Zipper (GILZ), an intracellular protein widely expressed in immune tissues, has been reported in epithelial tissues and controls some of key signaling pathways involved in tumorigenesis.
  • The objectives of the current study were to examine the expression of GILZ in EOC and its effect on tumor cell proliferation.
  • RESULTS: GILZ expression was measured by immunohistochemical staining in tissue sections from 3 normal ovaries, 7 benign EOC and 50 invasive EOC.
  • GILZ was not detected on the surface epithelium of normal ovaries and benign tumors.
  • In contrast, it was expressed in the cytoplasm of tumor cells in 80% EOC specimens.
  • They were also higher in tumor cells containing large amounts of phosphorylated protein kinase B (p-AKT) (unpaired t test, P < 0.0001).
  • To assess the effect of GILZ on proliferation and AKT activation, we used the BG-1 cell line derived from ovarian tumor cells as a cellular model.
  • CONCLUSION: The present study is the first to identify GILZ as a molecule produced by ovarian cancer cells that promotes cell cycle progression and proliferation.
  • [MeSH-major] Epithelial Cells / pathology. Ovarian Neoplasms / pathology. Transcription Factors / metabolism


29. Aikhionbare FO, Mehrabi S, Kumaresan K, Zavareh M, Olatinwo M, Odunsi K, Partridge E: Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages. J Carcinog; 2007 Jan 26;6:1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages.
  • BACKGROUND: A majority of primary ovarian neoplasms arise from cell surface epithelium of the ovaries.
  • Although old age and a positive family history are associated risk factors, the etiology of the epithelial ovarian tumors is not completely understood.
  • Additionally, knowledge of factors involved in the histogenesis of the various subtypes of this tumor as well as those factors that promote progression to advanced stages of ovarian malignancy are largely unknown.
  • METHODS: In this study, we determined the presence of polymorphisms and other sequence variants of mitochondrial DNA (mtDNA) in 102 epithelial ovarian tumors including 10 matched normal tissues that paired with some of the tumors.
  • Furthermore, two mutations were observed in serous tumors only at np 1657 in stage IV (10/10), and at np 8221delA in benign cystadenomas (3/3) and borderline tumors (4/4).
  • A high frequency, 81% (13/16) of TC insertion at np 310 was found only in early stages of serous subtype (benign cystadenomas, 3/3; borderline tumors, 4/4; stage I tumors, 2/5 and matched normal tissues 4/4).
  • CONCLUSION: Our findings indicate that certain mtDNA mutations can reliably distinguish the different histologic subtypes of epithelial ovarian tumors.
  • In addition, these data raise the possibility that certain mtDNA mutations may be useful biomarkers for predicting tumor aggressiveness and may play a potential role in tumorigenesis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24 [15647368.001]
  • [Cites] Nat Genet. 1998 Nov;20(3):291-3 [9806551.001]
  • [Cites] Biochim Biophys Acta. 1999 Feb 9;1410(2):103-23 [10076021.001]
  • [Cites] Eur J Cancer. 1999 Feb;35(2):316-9 [10448277.001]
  • [Cites] Mutat Res. 1999 Jul 30;434(3):177-203 [10486591.001]
  • [Cites] Science. 2000 Mar 17;287(5460):2017-9 [10720328.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4231-7 [10945635.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5007-11 [11016619.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1843-5 [11280735.001]
  • [Cites] Mutat Res. 2001 May;488(2):119-33 [11344040.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38555-62 [11504725.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5998-6001 [11507041.001]
  • [Cites] Am J Kidney Dis. 2001 Sep;38(3):529-36 [11532685.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7015-9 [11585726.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7623-6 [11606403.001]
  • [Cites] J Hum Genet. 2002;47(3):122-30 [11950064.001]
  • [Cites] Nucleic Acids Res. 2002 Jul 1;30(13):2817-24 [12087165.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2260-5 [12114429.001]
  • [Cites] J Pathol. 2003 Feb;199(2):237-42 [12533837.001]
  • [Cites] Cancer Lett. 2003 Feb 10;190(1):73-7 [12536079.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1838-43 [12578990.001]
  • [Cites] J Surg Oncol. 2003 Mar;82(3):170-3 [12619060.001]
  • [Cites] Hum Mutat. 2003 Apr;21(4):441-3 [12655558.001]
  • [Cites] Genetics. 1992 Jan;130(1):153-62 [1346260.001]
  • [Cites] Oncogene. 2004 Feb 12;23(6):1314-20 [14647457.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(2):99-105 [14999140.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4466-77 [15016645.001]
  • [Cites] Mol Cancer Res. 2004 Aug;2(8):433-41 [15328370.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:30 [15482594.001]
  • [Cites] BMC Cancer. 2006;6:21 [16433919.001]
  • [Cites] Mutat Res. 2006 Mar 20;595(1-2):42-51 [16472830.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:259-66 [16515601.001]
  • [Cites] Hum Pathol. 1991 Aug;22(8):750-62 [1869263.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:208-18 [8747398.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):514-9 [9012815.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • (PMID = 17257433.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / P20 MD000272
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC1794240
  •  go-up   go-down


30. Zhou JW, Gan NY, Zhang WJ: [The expression of MKP-1 and p-ERK(1/2) in primary ovarian epithelial tumor tissues]. Fen Zi Xi Bao Sheng Wu Xue Bao; 2009 Jun;42(3-4):224-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of MKP-1 and p-ERK(1/2) in primary ovarian epithelial tumor tissues].
  • To investigate the expression of mitogen activated protein kinase phosphatase-1 (MKP-1) and phosphorylation extracellular signal-regulated kinases (p-ERK(1/2)) in primary ovarian epithelial tumor tissues, and provide experiment's foundation on the new treatment in ovarian cancer.
  • Expression of MKP-1 and p-ERK(1/2) in tissues from 64 patients with primary ovarian epithelial tumor, 35 patients with ovarian epithelial bordline tumor, 32 patients with ovarian epithelial benign tumor and 26 normal ovarian tissues was detected by immunohistochemistry.
  • Immunohistochemistry and Western-blot assay showed that the expression of MKP-1 was gradually decreased in normal ovarian tissues, benign tumor, bordline tumor and carcinoma respectively, and there were significant differences among them (P < 0.01).
  • However, the expression of p-ERK(1/2) was gradually increased in normal ovarian tissues, benign tumor, bordline tumor and carcinoma respectively, and there were also significant differences among them (P < 0.01), the p-ERK(1/2) expression level in the carcinoma tissues of stage III/IV patients was significantly higher than that of stage I/II patients.
  • Expression of MKP-1 and p-ERK(1/2) in same ovarian carcinoma tissues detected by immunohistochemistry and Western-blot assay showed significant negative correlation (r = -0.90, P < 0.01 and r = -0.78, P < 0.01 respectively).
  • The expression changes of MKP-1 and ERKs may play a role in the development of ovarian carcinoma.
  • The abnormal expression of MKP-1 and p-ERK(1/2) probably assists in promoting the development and progression of ovarian carcinoma.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697705.001).
  • [ISSN] 1673-520X
  • [Journal-full-title] Fen zi xi bao sheng wu xue bao = Journal of molecular cell biology
  • [ISO-abbreviation] Fen Zi Xi Bao Sheng Wu Xue Bao
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.1.3.48 / Dual Specificity Phosphatase 1
  •  go-up   go-down


31. Nazlioglu HO, Ercan I, Bilgin T, Ozuysal S: Expression of p16 in serous ovarian neoplasms. Eur J Gynaecol Oncol; 2010;31(3):312-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p16 in serous ovarian neoplasms.
  • PURPOSE: We aimed to examine p16 protein expression in ovarian serous neoplasms along with normal ovarian tissues.
  • MATERIALS AND METHODS: P16 expression was immunhistochemically evaluated in 86 ovarian serous neoplasms (21 cystadenomas, 20 borderline tumors and 45 carcinomas) and 21 non-neoplastic ovarian tissue.
  • RESULTS: P16 expression rates for benign, borderline ovarian tumors and ovarian cancer were 14.2%, 85% and 86.6%, respectively.
  • No immunoreactivity was found in the non-neoplastic ovarian surface epithelial cells.
  • CONCLUSION: P16 expression is strong and widespread involving most tumor cells in serous papillary ovarian carcinomas, and is probably an early event.
  • [MeSH-major] Cystadenocarcinoma, Serous / chemistry. Neoplasm Proteins / analysis. Ovarian Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21077476.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P16 protein, human
  •  go-up   go-down


32. Cody NA, Shen Z, Ripeau JS, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN: Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. Mol Carcinog; 2009 Dec;48(12):1077-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer.
  • The genetic analysis of nontumorigenic radiation hybrids generated by transfer of chromosome 3 fragments into the tumorigenic OV-90 ovarian cancer cell line identified the 3p12.3-pcen region as a candidate tumor suppressor gene (TSG) locus.
  • The expression of all but one (VGLL3) of these genes was also detected in the parental OV-90 cell line.
  • Mutations were not identified in a comparative sequence analysis of the predicted protein coding regions of these candidates in OV-90 and donor normal chromosome 3 contig.
  • Interestingly, underexpression of VGLL3 and ZNF654 were observed in malignant ovarian tumor samples as compared with primary cultures of normal ovarian surface epithelial cells or benign ovarian tumors, and this occurred regardless of allelic content of 3p12.3-pcen.
  • The results taken together suggest that dysregulation of VGLL3 and/or ZNF654 expression may have affected pathways important in ovarian tumorigenesis which was offset by the transfer of chromosome 3 fragments in OV-90, a cell line hemizygous for 3p.
  • [MeSH-major] Chromosomes, Human, Pair 3 / genetics. Cystadenocarcinoma, Serous / genetics. Genes, Tumor Suppressor / physiology. Ovarian Neoplasms / genetics
  • [MeSH-minor] Alternative Splicing. Case-Control Studies. Cell Line, Tumor. DNA Methylation. DNA Primers / chemistry. DNA Primers / genetics. Female. Humans. Loss of Heterozygosity. Microsatellite Repeats. Ovary / metabolism. Ovary / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19347865.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


33. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW: Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res; 2006 Jan 15;12(2):432-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.
  • PURPOSE: The objective was to identify and characterize low molecular weight proteins/peptides in urine and their posttranslational modifications that might be used as a screening tool for ovarian cancer.
  • EXPERIMENTAL DESIGN: Urine samples collected preoperatively from postmenopausal women with ovarian cancer and benign conditions and from nonsurgical controls were analyzed by surface-enhanced laser desorption/ionization mass spectrometry and two-dimensional gel electrophoresis.
  • Quantitative and semiquantitative ELISAs were developed for preliminary validation in patients of 128 ovarian cancer, 52 benign conditions, 44 other cancers, and 188 healthy controls.
  • RESULTS: A protein (m/z approximately 17,400) with higher peak intensities in cancer patients than in benign conditions and controls was identified and subsequently defined as eosinophil-derived neurotoxin (EDN).
  • A glycosylated form of EDN was specifically elevated in ovarian cancer patients.
  • Modified forms EDN and osteopontin fragments were elevated in early-stage ovarian cancers and a combination of both resulted to 93% specificity and 72% sensitivity.
  • CONCLUSIONS: Specific elevated posttranslationally modified urinary EDN and osteopontin COOH-terminal fragments in ovarian cancer might lead to potential noninvasive screening tests for early diagnosis.
  • [MeSH-major] Biomarkers, Tumor / urine. Eosinophil-Derived Neurotoxin / urine. Neoplasms, Glandular and Epithelial / urine. Ovarian Neoplasms / urine. Sialoglycoproteins / urine
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Clear Cell / urine. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / urine. Amino Acid Sequence. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Carcinoma, Endometrioid / urine. Case-Control Studies. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Cystadenocarcinoma, Serous / urine. Electrophoresis, Gel, Two-Dimensional. Enzyme-Linked Immunosorbent Assay. Female. Glycosylation. Humans. Molecular Sequence Data. Neoplasm Invasiveness. Osteopontin. Prognosis. Proteome. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2006 Jan 15;12(2):323-7 [16428467.001]
  • (PMID = 16428483.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA 105009; United States / NCI NIH HHS / CA / R21 CA 111949-01; United States / NCI NIH HHS / CA / U01 CA 86381
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin; EC 3.1.- / Eosinophil-Derived Neurotoxin
  •  go-up   go-down


34. McBroom JW, Acs G, Rose GS, Krivak TC, Mohyeldin A, Verma A: Erythropoietin receptor function and expression in epithelial ovarian carcinoma. Gynecol Oncol; 2005 Dec;99(3):571-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythropoietin receptor function and expression in epithelial ovarian carcinoma.
  • OBJECTIVE: Our objectives were to determine if the erythropoietin receptor (EpoR) has increased expression in epithelial ovarian carcinoma, and if erythropoietin (Epo) confers malignant properties to ovarian cancer cell lines.
  • METHODS: A Western blot analysis of protein lysates from normal ovarian surface epithelial cells and ovarian cancer cell lines was performed.
  • In addition, immunohistochemical (IHC) staining for EpoR in tissue specimens of normal, low malignant potential tumor, and epithelial ovarian carcinoma was performed.
  • Epo effect on ovarian cancer cell lines was investigated by a cytotoxicity assay using a cell line with high (OVCAR3) and low (SKOV3) EpoR expression.
  • RESULTS: Western blot analysis revealed increased expression of EpoR in multiple ovarian cancer cell lines.
  • IHC staining revealed limited EpoR expression in benign ovarian tissue and increased levels in ovarian low malignant potential (LMP) tumor and carcinoma.
  • This difference between benign ovarian tissue and carcinoma was found to be statistically significant using a quantitative scoring system.
  • CONCLUSION: Increased EpoR expression in ovarian LMP tumors and carcinoma is demonstrated by Western blot analysis and IHC staining.
  • Furthermore, adversely effects sensitivity to cisplatin in the ovarian cancer cell lines.
  • [MeSH-major] Ovarian Neoplasms / metabolism. Receptors, Erythropoietin / physiology
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Blotting, Western. Cell Line, Tumor. Cisplatin / pharmacology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Drug Screening Assays, Antitumor. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16051335.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Erythropoietin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


35. Ota T, Gilks CB, Longacre T, Leung PC, Auersperg N: HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. Reprod Sci; 2007 Sep;14(6):605-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
  • Interrelationships between HOXA7 expression and ovarian cancer progression are investigated by cDNA array and by immunohistochemistry of normal ovaries and 538 epithelial ovarian tumor microarrays.
  • HOXA7 mRNA expression was higher in carcinomas than in benign tumors.
  • HOXA7 protein was absent in normal surface epithelium but appeared in metaplastic regions.
  • There were significant associations of strong HOXA7 staining of stroma and tumor nuclei with the clear cell histotype (stroma: P = .0022, nuclei: P = .0003) and of weak/absent staining with serous carcinomas.
  • Tumor E-cadherin expression correlated significantly with HOX7 staining in stroma (P = .0002) but not within tumors.
  • HOXA7 staining of tumor cell nuclei is correlated significantly with improved disease-specific survival (P = .0104), which is suggestive of the biological and potentially clinical importance of subcellular HOXA7 localization.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemistry. Adenocarcinoma, Mucinous / chemistry. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Cell Differentiation. Cystadenocarcinoma, Serous / chemistry. Homeodomain Proteins / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Cadherins / analysis. Cell Nucleus / chemistry. Cluster Analysis. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Metaplasia. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. Stromal Cells / chemistry. Stromal Cells / pathology. Tissue Array Analysis


36. Hopfer O, Zwahlen D, Fey MF, Aebi S: The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer; 2005 Sep 19;93(6):709-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Notch pathway in ovarian carcinomas and adenomas.
  • Elements of the Notch pathway regulate differentiation; we investigated the expression of such elements in epithelial ovarian tumours.
  • A total of 32 ovarian tumour samples (17 adenocarcinomas, three borderline tumours, 12 adenomas), two human ovarian cancer (A2780, OVCAR3), and one ovarian surface (IOSE 144) cell lines were analysed.
  • Quantitative PCR revealed decreased Notch 1 mRNA in ovarian adenocarcinomas compared with adenomas.
  • The expression of Notch 1-EC protein was similar in benign and malignant tumours.
  • HES1 protein was strongly expressed in 18/19 ovarian cancers and borderline tumours but not in adenomas.
  • Thus, Notch pathway elements are expressed in ovarian epithelial tumours and some of them are differentially expressed between adenomas and carcinomas.
  • The Notch pathway could be a target for the development of therapies for ovarian cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Membrane Proteins / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Signal Transduction
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Basic Helix-Loop-Helix Transcription Factors. Cell Proliferation. Female. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Humans. Middle Aged. Ovary / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Notch. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(7):1099-102 [10584867.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6414-8 [7604005.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):66-70 [10962441.001]
  • [Cites] Oncogene. 2000 Aug 31;19(37):4191-8 [10980592.001]
  • [Cites] Int J Oncol. 2000 Dec;17(6):1131-9 [11078798.001]
  • [Cites] Curr Opin Mol Ther. 2000 Feb;2(1):55-65 [11249652.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3200-5 [11306509.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] EMBO J. 2001 Jul 2;20(13):3427-36 [11432830.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5925-34 [11486031.001]
  • [Cites] Neuron. 2001 Aug 30;31(4):557-68 [11545715.001]
  • [Cites] Genes Dev. 1995 Nov 1;9(21):2609-22 [7590239.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):952-9 [8622698.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:208-18 [8747398.001]
  • [Cites] J Biol Chem. 1997 May 30;272(22):14110-4 [9162037.001]
  • [Cites] Am J Hum Genet. 1998 Mar;62(3):676-89 [9497246.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2077-88 [9528780.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2095-7 [9605750.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):214-9 [9874798.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2431-48 [10194420.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] EMBO J. 1999 May 17;18(10):2803-11 [10329626.001]
  • [Cites] J Cell Physiol. 1999 Dec;181(3):393-409 [10528225.001]
  • [Cites] Oncol Rep. 2005 Mar;13(3):375-87 [15706405.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7291-7 [11585768.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7426-9 [11606375.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):719-24 [11641404.001]
  • [Cites] Oncogene. 2001 Dec 20;20(58):8342-57 [11840327.001]
  • [Cites] Blood. 2002 May 1;99(9):3398-403 [11964309.001]
  • [Cites] Nat Med. 2002 Sep;8(9):979-86 [12185362.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] J Clin Invest. 2002 Oct;110(8):1165-74 [12393852.001]
  • [Cites] Biochemistry. 2003 Jan 14;42(1):137-44 [12515548.001]
  • [Cites] FASEB J. 2003 Jan;17(1):79-81 [12424225.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1777-83 [12406868.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):416-21 [12590261.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):1988-97 [12673204.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(18):6694-701 [12944493.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6598-608 [14528285.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):48-54 [15108805.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] Anticancer Res. 1989 Nov-Dec;9(6):1537-47 [2697181.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Am J Pathol. 1991 Oct;139(4):777-85 [1656759.001]
  • [Cites] Blood. 1992 Feb 15;79(4):981-9 [1737106.001]
  • [Cites] Int J Cancer. 1992 Mar 12;50(5):828-33 [1544716.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9267-71 [1409633.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4961-5 [8506342.001]
  • [Cites] Biochem J. 2000 May 1;347 Pt 3:719-24 [10769175.001]
  • (PMID = 16136053.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Homeodomain Proteins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Receptors, Notch; 149348-15-2 / HES1 protein, human
  • [Other-IDs] NLM/ PMC2361628
  •  go-up   go-down


37. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M: Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int; 2009 May;59(5):300-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors.
  • Tumor-associated macrophages (TAM) are known to possess the immunosuppressive M2 macrophage phenotype.
  • They contribute to tumor growth, invasion, and metastasis by producing various mediators.
  • Macrophages, especially M2 polarized macrophages, preferentially express CD163 and CD204, but few studies have investigated macrophage phenotypes in human ovarian tumors.
  • The purpose of the present study was therefore to present results on macrophage differentiation in human ovarian serous and mucinous epithelial tumors.
  • The method focused on immunostaining of paraffin-embedded tumor samples.
  • Almost all macrophages infiltrating tumor tissues expressed CD163 and CD204, indicating the phenotypic shift toward M2 macrophage.
  • The numbers of CD68-positive macrophages as well as of CD163- and CD204-positive macrophages in borderline and malignant tumors were significantly higher than in benign tumors.
  • CSF-1 expression in malignant tumor cells was significantly higher than that in benign tumor cells and correlated with histological malignancy.
  • These results suggest that CSF-1 derived from tumor tissues induces macrophages to shift toward the M2 phenotype, which is considered to promote tumor growth.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / immunology. Cystadenocarcinoma, Serous / immunology. Macrophage Colony-Stimulating Factor / biosynthesis. Macrophages / immunology. Ovarian Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Antigens, CD / immunology. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / immunology. Antigens, Differentiation, Myelomonocytic / metabolism. Cell Differentiation / immunology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness / immunology. Phenotype. Receptors, Cell Surface / immunology. Receptors, Cell Surface / metabolism. Scavenger Receptors, Class A / immunology. Scavenger Receptors, Class A / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432671.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD163 antigen; 0 / MSR1 protein, human; 0 / Receptors, Cell Surface; 0 / Scavenger Receptors, Class A; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


38. Chen X, Horiuchi A, Kikuchi N, Osada R, Yoshida J, Shiozawa T, Konishi I: Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: it's inhibition leads to growth suppression and apoptosis. Cancer Sci; 2007 Jan;98(1):68-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: it's inhibition leads to growth suppression and apoptosis.
  • However, little is known about its role in the development or patient prognosis of epithelial ovarian carcinoma.
  • In the present study, we examined in vivo and in vitro the expression and functional role of Hh signal molecules in epithelial ovarian tumors and normal ovarian surface epithelial (OSE) cells.
  • The expression of Shh, Dhh, Ptch, Smo and Gli1 proteins was not observed in normal OSE, but was increased stepwise in benign, borderline and malignant neoplasms.
  • Blocking the Hh signal using either the Hh pathway inhibitor cyclopamine or Gli1 siRNA led to remarkably decreased cell proliferation in ovarian carcinoma cells.
  • Among the Hh signal molecules, Dhh expression was correlated with poor prognosis of ovarian carcinoma patients.
  • These findings suggest that the Hh signal pathway plays an important role in ovarian tumorigenesis as well as in the activation of cell proliferation in ovarian carcinomas.
  • Thus, the Hh signal pathway is a possible molecular target of new treatment strategies for ovarian carcinoma.
  • [MeSH-major] Apoptosis / physiology. Biomarkers, Tumor / analysis. Cell Proliferation. Hedgehog Proteins / metabolism. Ovarian Neoplasms / metabolism. Signal Transduction / physiology
  • [MeSH-minor] Cell Line, Tumor. DNA Mutational Analysis. Female. Flow Cytometry. Humans. Immunoblotting. Immunohistochemistry. Prognosis. RNA Interference. Reverse Transcriptase Polymerase Chain Reaction


39. Gwin K, Mariño-Enríquez A, Martel M, Reyes-Múgica M: Sclerosing stromal tumor: an important differential diagnosis of ovarian neoplasms in childhood and adolescence. Pediatr Dev Pathol; 2009 Sep-Oct;12(5):366-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing stromal tumor: an important differential diagnosis of ovarian neoplasms in childhood and adolescence.
  • Sclerosing stromal tumors are an uncommon type of benign ovarian sex cord-stromal tumor.
  • Although the usual age of presentation is in the 2nd and 3rd decades, sclerosing stromal tumor can occur in adolescence or premenarchal girls.
  • Imaging studies frequently reveal solid or complex cystic adnexal masses with marked vascularity raising concern for germ cell tumors and, especially in the absence of elevated tumor markers, surface epithelial neoplasms.
  • The differential diagnosis of a benign sclerosing stromal tumor is seldom entertained.
  • We stress the importance of being familiar with sclerosing stromal tumors when evaluating ovarian neoplasms in children and adolescents in order to contribute to the appropriate clinical management preventing extensive and unnecessary surgery, and preserving fertility.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19071970.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Zhang S, Wei L, Zhang A, Zhang L, Yu H: RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines. OMICS; 2009 Aug;13(4):307-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines.
  • RUNX3 is an important tumor suppressor gene located on human chromosome 1p36.1, and many tumors do not express it due to methylation of the promoter region of the CpG island.
  • The molecular mechanisms involved in RUNX3 gene expression and epithelial ovarian cancer are not fully understood.
  • This study investigates the relationship between RUNX3 methylation and expression in ovarian cancer.
  • The methylation of the RUNX3 gene promoter region was measured in 32 primary epithelial ovarian cancer samples and corresponding nonmalignant ovarian tissues, 36 benign epithelial ovarian tumor tissues, and 10 normal ovarian tissues by methylation-specific PCR (MSP) and RT-PCR.
  • We detected RUNX3 methylation in 53.1% of primary ovarian cancer tumors, 16.7% of benign ovarian tumors, and 28% of nonmalignant tissues surrounding ovarian cancers.
  • No methylation was detected in normal ovarian tissues.
  • The RT-PCR results found RUNX3 expression in all normal ovarian tissues (10/10) and in most of the unmethylated ovarian cancer tissues (12/15); in contrast, it was not detected in most of the RUNX3-methylated ovarian cancer tissues (16/17).
  • Our data suggest that methylation plays a critical role in the regulation of RUNX3 repression, and that it is significantly correlated with RUNX3 mRNA expression in ovarian cancer tissues (p = 0.006).
  • [MeSH-major] Core Binding Factor Alpha 3 Subunit / metabolism. DNA Methylation. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Cell Line, Tumor. CpG Islands. DNA Modification Methylases / antagonists & inhibitors. Enzyme Inhibitors / pharmacology. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Promoter Regions, Genetic. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645591.001).
  • [ISSN] 1557-8100
  • [Journal-full-title] Omics : a journal of integrative biology
  • [ISO-abbreviation] OMICS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 3 Subunit; 0 / Enzyme Inhibitors; 0 / RNA, Messenger; 0 / Runx3 protein, human; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; M801H13NRU / Azacitidine
  •  go-up   go-down


41. Guo DH, Pang SJ, Shen Y: [Atypical endometriosis: a clinicopathologic study of 163 cases]. Zhonghua Fu Chan Ke Za Zhi; 2008 Nov;43(11):831-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathologic changes of AEM including its glandular epithelium, stroma, background and the conditions coexisting with tumor were observed.
  • Of 172 AEM foci of 163 patients, 168 were in the ovary, and the other 4 were in the fallopian tube, cervix and uterine serosa respectively.
  • The rate of ovarian AEM was 6.81% of endometriosis.
  • AEM associated with tumour was found in 26 cases (15.95%) and among 27 of ovarian AEM, 15 were malignant, 9 borderline and 3 benign.
  • The AEM epithelia were mainly arranged in the form of surface epithelium.
  • They present with characteristic features of moderate to marked pleomorphism, epithelial tufting and bud structures by microscopy.
  • The transformation from AEM to tumor was found in most of the malignant tumors (14/15, 93%).
  • CONCLUSIONS: AEM lesions hold some features of both EM and tumor, which may have a relatively higher potential for tumorigenesis and canceration.
  • The process of damage and repair in EM foci during a long course may play a role in the development of EM into AEM and finally into tumor.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometriosis / pathology. Epithelium / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenosarcoma / complications. Adenosarcoma / epidemiology. Adenosarcoma / pathology. Adolescent. Adult. Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Young Adult


42. Gursan N, Sipal S, Calik M, Gundogdu C: P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms. Eurasian J Med; 2009 Apr;41(1):10-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms.
  • OBJECTIVE: Approximately 50% of human malignancies present with mutations in p53, which is the most common tumor suppressor gene involved with human malignancies.
  • The purpose of this study was to determine whether simultaneous detection of p53, bcl-2 and Ki-67 using immunohistochemical staining can be used as a diagnostic factor in the assessment of human ovarian epithelial tumors.
  • MATERIALS AND METHODS: The study was performed on formalin-fixed, paraffin-embedded tissue samples from 75 epithelial ovarian tumors, 15 serous cystadenomas, 15 mucinous cystadenomas, 5 borderline serous cystadenomas, 5 borderline mucinous cystadenomas, 15 serous cystadenocarcinomas, 15 mucinous cystadenocarcinomas and 5 endometrioid carcinomas.
  • RESULTS: Anti-p53 reactivity was observed in 14 tumors, all of which were malignant tumors, and no reactivity was observed in borderline or benign tumors.
  • Overexpression of bcl-2 was observed in 12 benign neoplasms (40%), 5 of which were borderline (50%), but was not observed in any of the malignant tumors.
  • There was a statistically significantly higher level of Ki-67 LI positivity in the malignant tumors than in the benign and borderline tumors (p<0.005).
  • CONCLUSION: These data show significant differences in the expression of these markers in ovarian tumors and suggest a possible role for these tumor-associated genes as supplemental tools in diagnostic pathology.
  • Furthermore, our findings support the redesignation of low malignant potential tumors (current nomenclature) to benign ovarian carcinoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25610057.001).
  • [ISSN] 1308-8734
  • [Journal-full-title] The Eurasian journal of medicine
  • [ISO-abbreviation] Eurasian J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC4261648
  • [Keywords] NOTNLM ; Ki-67 / Ovarian cancer / bcl-2 / p53
  •  go-up   go-down


43. Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, Gazdar AF, Schorge JO: Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res; 2005 Aug 1;11(15):5365-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation profile of ovarian epithelial neoplasms.
  • PURPOSE: Ovarian carcinomas are believed to arise de novo from surface epithelium, but the actual molecular pathogenesis is unknown.
  • The aim of this study was to compare the promoter hypermethylation profiles of ovarian epithelial neoplasms to better understand the role of epigenetic silencing in carcinogenesis.
  • EXPERIMENTAL DESIGN: We analyzed the DNA promoter methylation status of eight tumor suppressor and cancer-related genes (p16, RARbeta, E-cadherin,H-cadherin, APC, GSTP1, MGMT, RASSF1A) in 23 benign cystadenomas, 23 low malignant potential (LMP) tumors, and 23 invasive carcinomas by methylation-specific PCR.
  • RESULTS: Benign cystadenomas exhibited promoter hypermethylation in only two genes, p16 (13%) and E-cadherin (13%).
  • CONCLUSIONS: Promoter hypermethylation is a frequent epigenetic event that occurs most commonly in invasive epithelial ovarian carcinomas.
  • The profile of aberrant methylation suggests that an accumulation of events at specific genes may trigger malignant transformation of some benign cystadenomas and LMP tumors.
  • [MeSH-major] DNA Methylation. Neoplasms, Glandular and Epithelial / genetics. Ovarian Neoplasms / genetics. Promoter Regions, Genetic
  • [MeSH-minor] Adenomatous Polyposis Coli Protein / genetics. Adult. Aged. Aged, 80 and over. Cadherins / genetics. Carcinoma / genetics. Carcinoma / pathology. Cell Transformation, Neoplastic. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Cystadenoma / genetics. DNA / metabolism. Epigenesis, Genetic. Female. Gene Silencing. Glutathione S-Transferase pi / genetics. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. O(6)-Methylguanine-DNA Methyltransferase / genetics. Polymerase Chain Reaction. Receptors, Retinoic Acid / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061849.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Cadherins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / H-cadherin; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta; 9007-49-2 / DNA; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


44. Khunamornpong S, Lerwill MF, Siriaunkgul S, Suprasert P, Pojchamarnwiputh S, Chiangmai WN, Young RH: Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases. Int J Gynecol Pathol; 2008 Jul;27(3):366-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases.
  • Information on ovarian metastasis of carcinoma of the extrahepatic bile ducts and gallbladder is limited.
  • The patients ranged from 21 to 87 years (mean, 59 years); 7 presented to gynecologists with nonspecific pelvic symptoms similar to primary ovarian neoplasms.
  • The primary tumor was identified before the detection of the ovarian lesions in 5 cases, was simultaneously detected with the ovarian metastases in 9, and was diagnosed postoperatively in 2.
  • All but one case had bilateral ovarian involvement.
  • The thirty-one ovarian lesions included twenty-nine grossly abnormal ovaries that were enlarged (range, 3.0-16.5 cm, mean, 9.4 cm) and 2 ovaries with only microscopic involvement.
  • The sectioned surface was solid in 9, solid-cystic in 15, and multicystic in 5.
  • Microscopically, ovarian surface implants were seen in 66%, multinodular growth in 58%, and infiltrative stromal invasion in 81%.
  • Mucinous epithelial differentiation was seen in 81%, sometimes with foci of benign-like or borderline-like epithelium simulating primary ovarian mucinous neoplasia.
  • Signet ring cells were present in sufficient quantity for a diagnosis of Krukenberg tumor in four tumors.
  • Nonmucinous carcinomatous components included adenocarcinoma with high-grade endometrioid-like morphology in 2 cases, papillary adenocarcinoma simulating mixed müllerian epithelial adenocarcinoma in 1, and undifferentiated carcinoma in 2.
  • The high rate of bilaterality, surface involvement, multinodular growth, and heterogeneity of patterns were the most helpful features for indicating a metastatic nature, with signet ring cells also being helpful in the minority of cases in which they were present.
  • Although the diagnosis of a metastatic tumor to the ovary is possible in most of the cases based on standard diagnostic criteria, problems in the differential diagnosis may be posed by morphologic patterns that overlap strikingly with primary ovarian neoplasms, benign, borderline, and malignant, as discussed herein.
  • [MeSH-major] Adenocarcinoma / pathology. Bile Duct Neoplasms / pathology. Gallbladder Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580314.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Veras E, Deavers MT, Silva EG, Malpica A: Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol; 2007 May;31(5):774-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
  • Nonsmall cell neuroendocrine carcinoma (NSCNEC) of the ovary is a rare and aggressive tumor commonly associated with other surface epithelial and germ cell neoplasms.
  • In 8 cases, NSCNEC was associated with other epithelial neoplasms, including mucinous neoplasms of low malignant potential, mucinous carcinoma, endometrioid carcinoma, mixed endometrioid and mucinous carcinoma, and a high-grade carcinoma, not otherwise specified.
  • In 2 cases, the tumor was associated with a mature cystic teratoma; one of them also containing an invasive moderately differentiated adenocarcinoma.
  • A single case was associated with a benign ovarian cyst.
  • The latter case had a dermoid cyst in the contralateral ovary.
  • NSCNEC represented anywhere from 10% to 90% of the ovarian tumor.
  • In summary, ovarian NSCNEC is an aggressive tumor with a tendency to present at advanced stage and cause death within a mean of 17 months after diagnosis; however, some patients, particularly those with stage I disease and/or those who have received platinum-based therapy, may have a more favorable prognosis.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Neuroendocrine / pathology. Immunoenzyme Techniques. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460463.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


46. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ: Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol; 2005 Jan;96(1):48-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models.
  • OBJECTIVE: To evaluate subrenal capsule xenografting of primary ovarian tumor tissues in mice for development of new ovarian cancer models.
  • METHODS: Pieces (1 x 3 x 3 mm) of ovarian tumor specimens from patients were meticulously grafted under renal capsules of female NOD/SCID mice within 2 h of surgical removal.
  • Tumor types included papillary serous adenocarcinomas, borderline and benign mucinous cystadenomas, granulosa cell tumors, a serous borderline tumor and a grade 3 mixed surface epithelial tumor of transitional and undifferentiated types.
  • RESULTS: Tumor tissue engraftment rate was > 95%.
  • CONCLUSIONS: Subrenal capsule xenografts of primary human ovarian tumors in SCID mice can retain major histopathological and immunohistochemical characteristics of the original tissues.
  • The achievable, consistently high engraftment rate allows use of such xenografts as tools for studying a wide range of ovarian tumors, including granulosa cell tumors and benign, borderline, and malignant surface epithelial neoplasms.
  • Potential applications include preclinical testing of patients' tumor responses to various chemotherapeutic regimens, evaluation of novel therapeutic agents, analysis of tumor progression at cellular and molecular levels, and identification of new therapeutic targets.
  • [MeSH-major] Disease Models, Animal. Ovarian Neoplasms / pathology. Subrenal Capsule Assay
  • [MeSH-minor] Animals. Female. Humans. Immunophenotyping. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589579.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Freedman RS, Wang E, Voiculescu S, Patenia R, Bassett RL Jr, Deavers M, Marincola FM, Yang P, Newman RA: Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. Clin Cancer Res; 2007 Oct 1;13(19):5736-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer.
  • PURPOSE: To describe the eicosanoid profile and differentially expressed eicosanoid and arachidonic acid pathway genes in tissues from patients with advanced epithelial ovarian cancer (EOC).
  • EXPERIMENTAL DESIGN: We first employed electrospray tandem mass spectrometry to determine tissue-specific concentrations of the eicosanoids prostaglandin E2 (PGE2), the hydroxyeicosatetraenoic acids (12-HETE and 5-HETE), and leukotriene (LTB4), selected for tumor growth potential, and two other bioactive lipids (15-HETE and 13-HODE) with tumor cell proliferation interference potential.
  • Tissues used included EOC tumor, tumor-free malignant peritoneum (MP), and benign peritoneum (BP) from patients with benign pelvic disease.
  • RESULTS: (a) Eicosanoid products were detected in tumor, MP, and BP specimens.
  • Neither 15-HETE nor 13-HODE showed a significant opposite trend toward levels found in BP. (b) Tissue specimens representing common EOC histotypes showed strong coexpressions of cyclooxygenases (COX-1) and prostaglandin E synthases (PGES-1) on tumor cells, whereas intratumoral or peritumoral MO/MA coexpressed COX-1 and COX-2 and PGES-1 and PGES-2, respectively. (c) cDNA microarray analysis of MP, BP, and tumor showed that a number of eicosanoid and arachidonic acid pathway genes were differentially expressed in MP and BP compared with tumor, except for CYP2J2, which was increased in tumors.
  • CONCLUSIONS: Elevated levels of eicosanoid metabolites in tumors and differential expression of eicosanoid and arachidonic acid pathway genes in the peritoneum support the involvement of bioactive lipids in the inflammatory tumor environment of EOC.
  • [MeSH-major] Eicosanoids / metabolism. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Peritoneum / metabolism
  • [MeSH-minor] Antigens, CD / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Arachidonic Acid / chemistry. Dinoprostone / metabolism. Female. Gene Expression Profiling. Humans. Inflammation. Lipids / chemistry. Microscopy, Confocal. Models, Biological. Receptors, Cell Surface / biosynthesis. Spectrometry, Mass, Electrospray Ionization

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908963.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD163 antigen; 0 / Eicosanoids; 0 / Lipids; 0 / Receptors, Cell Surface; 27YG812J1I / Arachidonic Acid; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


48. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ: Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res; 2005 Nov 15;65(22):10602-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
  • Papillary serous low malignant potential (LMP) tumors are characterized by malignant features and metastatic potential yet display a benign clinical course.
  • The role of LMP tumors in the development of invasive epithelial cancer of the ovary is not clearly defined.
  • The aim of this study is to determine the relationships among LMP tumors and invasive ovarian cancers and identify genes contributing to their phenotypes.
  • Affymetrix U133 Plus 2.0 microarrays (Santa Clara, CA) were used to interrogate 80 microdissected serous LMP tumors and invasive ovarian malignancies along with 10 ovarian surface epithelium (OSE) brushings.
  • Gene expression profiles for each tumor class were used to complete unsupervised hierarchical clustering analyses and identify differentially expressed genes contributing to these associations.
  • The expression profiles of LMP, low-grade, and high-grade papillary serous ovarian carcinomas suggest that LMP tumors are distinct from high-grade cancers; however, they are remarkably similar to low-grade cancers.
  • Prominent expression of p53 pathway members may play an important role in the LMP tumor phenotype.
  • [MeSH-major] Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cluster Analysis. Female. Gene Expression Profiling. Humans. Neoplasm Staging. Oligonucleotide Array Sequence Analysis / methods. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288054.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


49. Penumatsa K, Edassery SL, Barua A, Bradaric MJ, Luborsky JL: Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. J Ovarian Res; 2010;3:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors.
  • BACKGROUND: We showed there are specific ALDH1 autoantibodies in ovarian autoimmune disease and ovarian cancer, suggesting a role for ALDH1 in ovarian pathology.
  • However, there is little information on the ovarian expression of ALDH1.
  • Therefore, we compared ALDH1 expression in normal ovary and benign and malignant ovarian tumors to determine if ALDH1 expression is altered in ovarian cancer.
  • Since there is also recent interest in ALDH1 as a cancer stem cell (CSC) marker, we assessed co-expression of ALDH1 with CSC markers in order to determine if ALDH1 is a potential CSC marker in ovarian cancer.
  • METHODS: mRNA and protein expression were compared in normal human ovary and serous ovarian tumors using quantitative Reverse-Transcriptase PCR, Western blot (WB) and semi-quantitative immunohistochemistry (IHC).
  • ALDH1 enzyme activity was confirmed in primary ovarian cells by flow cytometry (FC) using ALDEFLUOR assay.
  • RESULTS: ALDH1 mRNA expression was significantly reduced (p < 0.01; n = 5) in malignant tumors compared to normal ovaries and benign tumors.
  • The proportion of ALDH1+ cells was significantly lower in malignant tumors (17.1 ± 7.61%; n = 5) compared to normal ovaries (37.4 ± 5.4%; p < 0.01; n = 5) and benign tumors (31.03 ± 6.68%; p < 0.05; n = 5).
  • ALDH1+ cells occurred in the stroma and surface epithelium in normal ovary and benign tumors, although surface epithelial expression varied more in benign tumors.
  • Localization of ALDH1 was heterogeneous in malignant tumor cells and little ALDH1 expression occurred in poorly differentiated malignant tumors.
  • In benign tumors the distribution of ALDH1 had features of both normal ovary and malignant tumors.
  • CONCLUSIONS: Total ALDH1 expression is significantly reduced in malignant ovarian tumors while it is relatively unchanged in benign tumors compared to normal ovary.
  • Thus, ALDH1 expression in the ovary does not appear to be similar to breast, lung or colon cancer suggesting possible functional differences in these cancers.
  • SIGNIFICANCE: These observations suggest that reduced ALDH1 expression is associated with malignant transformation in ovarian cancer and provides a basis for further study of the mechanism of ALDH1 in this process.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Immunol. 2009 Feb;21(1):22-7 [18778953.001]
  • [Cites] Mol Cancer. 2008;7:87 [19025616.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Br J Cancer. 2009 Apr 7;100(7):1144-53 [19293794.001]
  • [Cites] Fertil Steril. 2010 Dec;94(7):2636-41 [20522323.001]
  • [Cites] Int J Cancer. 1994 Mar 1;56(5):743-8 [8314353.001]
  • [Cites] J Cell Physiol. 2000 Oct;185(1):1-20 [10942515.001]
  • [Cites] Endocrinology. 2000 Oct;141(10):3638-45 [11014218.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6744-9 [11118061.001]
  • [Cites] Annu Rev Nutr. 2002;22:347-81 [12055350.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Chem Biol Interact. 2003 Feb 1;143-144:201-10 [12604205.001]
  • [Cites] J Biochem Mol Toxicol. 2003;17(1):7-23 [12616643.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1013-20 [12631600.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1648-55 [15178579.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] FASEB J. 1991 Nov;5(14):2924-33 [1661245.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1092-100 [16969345.001]
  • [Cites] J Immunol. 2007 Sep 15;179(6):3724-33 [17785809.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10538-45 [17974998.001]
  • [Cites] J Cell Sci. 1991 Nov;100 ( Pt 3):657-66 [1808213.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] Mol Cancer Res. 2008 Jul;6(7):1146-53 [18644979.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8B):2236-52 [18681906.001]
  • [Cites] Int Immunol. 2009 Apr;21(4):361-77 [19190084.001]
  • [Cites] Mol Cancer Res. 2009 Mar;7(3):330-8 [19276181.001]
  • [Cites] Birth Defects Res C Embryo Today. 2009 Mar;87(1):64-89 [19306350.001]
  • [Cites] Mod Pathol. 2009 Jun;22(6):817-23 [19329942.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3382-9 [19336570.001]
  • [Cites] Nucl Recept Signal. 2009;7:e002 [19381305.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] Breast Cancer Res Treat. 2010 Aug;123(1):109-11 [19946740.001]
  • [Cites] Lab Invest. 2010 Feb;90(2):234-44 [20010854.001]
  • [Cites] Clin Cancer Res. 2010 Feb 1;16(3):876-87 [20103682.001]
  • [Cites] PLoS One. 2010;5(4):e10277 [20422001.001]
  • [Cites] Cell Commun Signal. 2010;8(1):6 [20459772.001]
  • [Cites] J Microsc. 1987 Sep;147(Pt 3):229-63 [3430576.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):146-7 [7707390.001]
  • [Cites] Neurobiol Aging. 1993 Jul-Aug;14(4):275-85 [8367009.001]
  • [Cites] Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S52-62 [8811064.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):54-62 [9103391.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2033-8 [9815594.001]
  • [Cites] J Investig Med. 1996 Feb;44(2):42-6 [8689400.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2157-63 [12727970.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] Mol Cancer. 2004 Oct 7;3:27 [15471544.001]
  • [Cites] J Endocrinol. 2004 Oct;183(1):19-28 [15525570.001]
  • [Cites] Hum Genomics. 2005 Jun;2(2):138-43 [16004729.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11707-12 [16857736.001]
  • [Cites] Cytometry B Clin Cytom. 2007 Jul;72(4):281-9 [17111384.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):340-9 [17920722.001]
  • [Cites] Toxicol Sci. 2008 Jan;101(1):51-64 [17998271.001]
  • [Cites] Endocrinology. 2008 Sep;149(9):4307-11 [18556344.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):697-720 [18611112.001]
  • (PMID = 21176222.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3022900
  •  go-up   go-down


50. Bazzaro M, Santillan A, Lin Z, Tang T, Lee MK, Bristow RE, Shih IeM, Roden RB: Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility. Am J Pathol; 2007 Nov;171(5):1640-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility.
  • Both tumor cell proliferation and metastasis are dependent on myosin II.
  • Because UNC-45 is required to chaperone the assembly of a functional myosin II motor, we examined the expression of the general cell (GC) UNC-45 isoform in ovarian tumors.
  • Serous carcinoma expressed elevated levels of GC UNC-45 compared with normal ovarian surface epithelium and benign cystadenoma.
  • Similarly, GC UNC-45 transcripts and protein levels were higher in ovarian cell lines than in immortalized ovarian surface epithelial cells.
  • Elevation of GC UNC-45 levels by ectopic expression enhanced the rate of ovarian cancer cell proliferation, whereas siRNA knockdown of GC UNC-45 suppressed proliferation without altering myosin II levels.
  • GC UNC-45 and myosin II also trafficked to the leading edges of ovarian cancer cells induced to move in a scratch assay.
  • Knockdown of GC UNC-45 reduced the spreading ability of ovarian cancer cells whereas it was enhanced by GC UNC-45 overexpression.
  • In sum, these findings implicate elevated GC UNC-45 protein expression in ovarian carcinoma proliferation and metastasis.
  • [MeSH-major] Intracellular Signaling Peptides and Proteins / physiology. Molecular Chaperones / physiology. Myosin Type II / physiology. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Animals. Cell Line, Transformed. Cell Line, Tumor. Cell Movement. Cell Proliferation. Female. Humans. Protein Isoforms / physiology. Rabbits

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Biol. 2005 Apr 26;15(8):R310-1 [15854900.001]
  • [Cites] Oncogene. 2004 Nov 25;23(55):8859-67 [15480432.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4152-61 [15961763.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13473-8 [16174742.001]
  • [Cites] Curr Biol. 2003 Apr 29;13(9):715-24 [12725728.001]
  • [Cites] APMIS. 2003 Apr;111(4):523-30 [12780528.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Aug;17(4):909-25, vii [12959182.001]
  • [Cites] Trends Biochem Sci. 2003 Oct;28(10):541-7 [14559183.001]
  • [Cites] Mol Biol Cell. 2003 Dec;14(12):4745-57 [12960430.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 23;313(4):992-7 [14706640.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2907-18 [15077153.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4813-21 [15269157.001]
  • [Cites] Cell. 2004 Aug 6;118(3):337-49 [15294159.001]
  • [Cites] Curr Biol. 2004 Sep 21;14(18):R806-18 [15380095.001]
  • [Cites] J Cell Sci. 2004 Oct 15;117(Pt 22):5313-21 [15454571.001]
  • [Cites] J Cell Biol. 2004 Oct 25;167(2):315-25 [15504913.001]
  • [Cites] Nature. 1989 Sep 28;341(6240):328-31 [2797149.001]
  • [Cites] J Cell Biol. 1993 Mar;120(6):1381-91 [8449984.001]
  • [Cites] Development. 1996 May;122(5):1499-511 [8625837.001]
  • [Cites] J Cell Biol. 1998 Nov 30;143(5):1215-25 [9832550.001]
  • [Cites] Curr Opin Cell Biol. 1999 Feb;11(1):26-33 [10047526.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2076-82 [10232591.001]
  • [Cites] Mol Biol Cell. 1999 May;10(5):1309-23 [10233146.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7234-42 [16243793.001]
  • [Cites] Trends Cell Biol. 2005 Dec;15(12):651-8 [16243528.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:252-7 [16343241.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Mol Cancer Ther. 2006 Mar;5(3):522-32 [16546966.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3754-63 [16585202.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4725-33 [16651425.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1197-208 [16731752.001]
  • [Cites] Adv Cancer Res. 2006;95:323-48 [16860662.001]
  • [Cites] BMC Biol. 2006;4:19 [16800887.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1123-32 [17363505.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7023-32 [16203796.001]
  • [Cites] J Cell Biol. 2000 Jan 24;148(2):375-84 [10648570.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Pancreas. 2002 Jan;24(1):34-41 [11741180.001]
  • [Cites] Science. 2002 Jan 25;295(5555):669-71 [11809970.001]
  • [Cites] J Cell Sci. 2002 Nov 1;115(Pt 21):3983-90 [12356904.001]
  • [Cites] J Cell Sci. 2002 Nov 1;115(Pt 21):4013-23 [12356907.001]
  • [Cites] J Cell Biol. 2005 Feb 14;168(4):619-31 [15716379.001]
  • [Cites] Eukaryot Cell. 2005 Mar;4(3):567-76 [15755919.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):355-66 [15864277.001]
  • (PMID = 17872978.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA122581
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Molecular Chaperones; 0 / Protein Isoforms; 0 / UNC45A protein, human; EC 3.6.1.- / Myosin Type II
  • [Other-IDs] NLM/ PMC2043524
  •  go-up   go-down


51. Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD: Overexpression of mammaglobin B in epithelial ovarian carcinomas. Gynecol Oncol; 2007 Jun;105(3):578-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of mammaglobin B in epithelial ovarian carcinomas.
  • OBJECTIVE: Mammaglobin B is a uteroglobin gene family member recently found highly differentially expressed in serous papillary ovarian cancer by gene expression profiling.
  • In order to evaluate its potential as a novel ovarian cancer biomarker, in this study we quantified and compared Mammaglobin B expression in various histologic types of epithelial ovarian carcinomas (EOC).
  • METHODS: Mammaglobin B expression was evaluated by real-time PCR and/or immunohistochemistry in fresh-frozen biopsies and paraffin-embedded tissues derived from a total of 137 patients including 69 primary EOC with different histologies, 28 serous papillary omental metastasis, 8 borderline tumors, 26 benign cystadenomas and 14 normal ovaries.
  • RESULTS: High levels of Mammaglobin B gene expression were detected in 100% (68 out of 68) of the ovarian cancer biopsies tested by real-time PCR.
  • In contrast, normal human ovarian surface epithelium (HOSE) expressed negligible levels of Mammaglobin B mRNA (EOC versus HOSE, p<0.01).
  • In agreement with real-time PCR results, EOC were found to express significantly higher levels of Mammaglobin B protein when compared to normal ovaries and benign cystadenomas (p<0.01).
  • CONCLUSIONS: Mammaglobin B gene is highly expressed in EOC and may represent a novel molecular marker for multiple histological types of ovarian cancer.
  • Additional studies to evaluate the clinical utility of Mammaglobin B as a diagnostic and/or therapeutic target in ovarian cancer are warranted.
  • [MeSH-major] Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / immunology. Uteroglobin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Cell Line, Tumor. Female. Gene Expression. Humans. Immunohistochemistry. Mammaglobin B. Middle Aged. Myelin Proteins. Polymerase Chain Reaction. Proteolipids. Secretoglobins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343903.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin B; 0 / Myelin Proteins; 0 / Neoplasm Proteins; 0 / Proteolipids; 0 / SCGB2A1 protein, human; 0 / Secretoglobins; 9060-09-7 / Uteroglobin
  •  go-up   go-down


52. Presneau N, Shen Z, Provencher D, Mes-Masson AM, Tonin PN: Identification of novel variant, 1484delG in the 3'UTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors. Int J Oncol; 2005 Jun;26(6):1621-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of novel variant, 1484delG in the 3'UTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors.
  • Previous studies have implicated the chromosomal region at 17q25 as harboring tumor suppressor genes based on the frequent loss of heterozygosity (LOH) observed in epithelial ovarian cancers (EOC).
  • In contrast to three other EOC cell lines (TOV81D, TOV112D and TOV21G) and primary cultures derived from normal ovarian surface epithelial cells (NOSE), sequence analysis of the cDNA revealed a deletion of G at position 1484 of the transcribed sequence which is located within the 3'UTR of H3F3B.
  • OV90 was derived from ascites fluid of an undifferentiated adenocarcinoma of ovarian origin.
  • The variant allele was identified in 1 of 65 (2%) healthy women with no prior history of cancer and in 5 participants with ovarian tumors comprising of 4 of 79 (5%) malignant EOC, none of 10 low malignancy potential tumors, and 1 of 8 (13%) benign tumors.
  • All carriers of the variant alleles were heterozygous and tumor samples did not exhibit preferential LOH of the normal allele.
  • One of 3 mucinous benign tumors also harbored the variant allele.
  • The functional significance of the variant is unknown, however its presence in rare subtypes of ovarian epithelial tumors warrants further investigation.
  • [MeSH-major] 3' Untranslated Regions / genetics. Histones / genetics. Loss of Heterozygosity. Neoplasms, Glandular and Epithelial / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Chromosome Mapping. Chromosomes, Human, Pair 17. Female. Humans. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870878.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / Histones
  •  go-up   go-down


53. Shibata K, Kajiyama H, Mizokami Y, Ino K, Nomura S, Mizutani S, Terauchi M, Kikkawa F: Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia. Gynecol Oncol; 2005 Jul;98(1):11-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
  • P-LAP is a cell surface aminopeptidase, and is a synonym for oxytocinase.
  • The authors evaluated P-LAP and GLUT4 expression in benign, borderline, and malignant ovarian epithelia.
  • METHODS: Histologic sections of formalin-fixed, paraffin-embedded specimens from 11 patients with benign serous or mucinous cystadenomas, 14 patients with serous or mucinous borderline tumors, and 80 patients with epithelial-ovarian adenocarcinomas (29 serous, 17 endometrioid, 14 mucinous, and 20 clear cell adenocarcinomas) were stained for P-LAP and GLUT4 using each polyclonal antibody.
  • Expressions of P-LAP and GLUT-4 in ovarian cancer cells were detected by Western blotting.
  • RESULTS: P-LAP immunoreactivity was detected in 2 of 11 benign cystadenomas.
  • None of the 11 benign ovarian tumors showed any immunoreactivity for GLUT4.
  • CONCLUSIONS: P-LAP and GLUT4 are available not only for the evaluation of ovarian epithelial malignancy, but also as targets for molecular therapy.
  • Further study to investigate the roles of P-LAP and GLUT4 in ovarian carcinoma is needed.
  • [MeSH-major] Cystinyl Aminopeptidase / biosynthesis. Monosaccharide Transport Proteins / biosynthesis. Muscle Proteins / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Growth Processes / physiology. Cell Line, Tumor. Epithelium / enzymology. Epithelium / metabolism. Female. Glucose Transporter Type 4. Humans. Middle Aged. Neoplasm Invasiveness. Ovarian Diseases / enzymology. Ovarian Diseases / metabolism. Ovarian Diseases / pathology. Transfection

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907336.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 4; 0 / Monosaccharide Transport Proteins; 0 / Muscle Proteins; 0 / SLC2A4 protein, human; EC 3.4.11.3 / Cystinyl Aminopeptidase; EC 3.4.11.3 / leucyl-cystinyl aminopeptidase
  •  go-up   go-down


54. Huang KC, Park DC, Ng SK, Lee JY, Ni X, Ng WC, Bandera CA, Welch WR, Berkowitz RS, Mok SC, Ng SW: Selenium binding protein 1 in ovarian cancer. Int J Cancer; 2006 May 15;118(10):2433-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selenium binding protein 1 in ovarian cancer.
  • Selenium binding protein 1 (SELENBP1) was identified to be the most significantly down-regulated protein in ovarian cancer cells by a membrane proteome profiling analysis.
  • SELENBP1 expression levels in 4 normal ovaries, 8 benign ovarian tumors, 12 borderline ovarian tumors and 141 invasive ovarian cancers were analyzed with immunohistochemical assay.
  • SELENBP1 expression was reduced in 87% cases of invasive ovarian cancer (122/141) and was significantly reduced in borderline tumors and invasive cancers (p<0.001).
  • Cox multivariate analysis within the 141 invasive cancer tissues showed that SELENBP1 expression score was a potential prognostic indicator for unfavorable prognosis of ovarian cancer (hazard ratio [HR], 2.18; 95% CI=1.22-3.90; p=0.009).
  • We investigated the effects of selenium and androgen on normal human ovarian surface epithelial (HOSE) cells and cancer cells.
  • Interestingly, SELENBP1 mRNA and protein levels were reduced by androgen and elevated by selenium treatment in the normal HOSE cells, whereas reversed responses were observed in the ovarian cancer cell lines.
  • These results suggest that changes of SELENBP1 expression in malignant ovarian cancer are an indicator of aberration of selenium/androgen pathways and may reveal prognostic information of ovarian cancer.
  • [MeSH-major] Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Selenium-Binding Proteins / biosynthesis. Selenium-Binding Proteins / physiology
  • [MeSH-minor] Aged. Androgens / physiology. Female. Gene Expression Profiling. Humans. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Prognosis. Proteome. RNA, Messenger / biosynthesis. Selenium / pharmacology. Survival Analysis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16380993.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA86381; United States / NCI NIH HHS / CA / CA94944; United States / NCI NIH HHS / CA / P50CA165009
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Proteome; 0 / RNA, Messenger; 0 / SELENBP1 protein, human; 0 / Selenium-Binding Proteins; H6241UJ22B / Selenium
  •  go-up   go-down


55. Menendez L, Walker LD, Matyunina LV, Totten KA, Benigno BB, McDonald JF: Epigenetic changes within the promoter region of the HLA-G gene in ovarian tumors. Mol Cancer; 2008;7:43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic changes within the promoter region of the HLA-G gene in ovarian tumors.
  • BACKGROUND: Previous findings have suggested that epigenetic-mediated HLA-G expression in tumor cells may be associated with resistance to host immunosurveillance.
  • To explore the potential role of DNA methylation on HLA-G expression in ovarian cancer, we correlated differences in HLA-G expression with methylation changes within the HLA-G regulatory region in an ovarian cancer cell line treated with 5-aza-deoxycytidine (5-aza-dC) and in malignant and benign ovarian tumor samples and ovarian surface epithelial cells (OSE) isolated from patients with normal ovaries.
  • RESULTS: A region containing an intact hypoxia response element (HRE) remained completely methylated in the cell line after treatment with 5-aza-dC and was completely methylated in all of the ovarian tumor (malignant and benign) samples examined, but only variably methylated in normal OSE samples.
  • HLA-G expression was significantly increased in the 5-aza-dC treated cell line but no significant difference was detected between the tumor and OSE samples examined.
  • CONCLUSION: Since HRE is the binding site of a known repressor of HLA-G expression (HIF-1), we hypothesize that methylation of the region surrounding the HRE may help maintain the potential for expression of HLA-G in ovarian tumors.
  • The fact that no correlation exists between methylation and HLA-G gene expression between ovarian tumor samples and OSE, suggests that changes in methylation may be necessary but not sufficient for HLA-G expression in ovarian cancer.
  • [MeSH-major] Epigenesis, Genetic. HLA Antigens / genetics. Histocompatibility Antigens Class I / genetics. Ovarian Neoplasms / genetics. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Adult. Aged. Azacitidine / pharmacology. Base Sequence. Cell Line, Tumor. CpG Islands / genetics. DNA Methylation / drug effects. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Gene Expression Regulation, Neoplastic / drug effects. HLA-G Antigens. Humans. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Transcription Initiation Site

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4510-5 [9539768.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1081-92 [14602239.001]
  • [Cites] Transplant Proc. 1999 Jun;31(4):1857-9 [10371973.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):928-36 [15514928.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):361-9 [14708716.001]
  • [Cites] Adv Immunol. 2003;81:199-252 [14711057.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Science. 1990 Apr 13;248(4952):220-3 [2326636.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Blood. 2005 Jan 15;105(2):659-69 [15374877.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10139-44 [16287995.001]
  • [Cites] J Exp Med. 2005 Dec 5;202(11):1493-505 [16330813.001]
  • [Cites] Cancer Invest. 2006 Mar;24(2):178-86 [16537188.001]
  • [Cites] Biochem Cell Biol. 2006 Aug;84(4):463-76 [16936820.001]
  • [Cites] Hum Immunol. 2007 Apr;68(4):277-85 [17400064.001]
  • [Cites] Ann Oncol. 2007 Nov;18(11):1804-9 [17846022.001]
  • [Cites] Semin Cancer Biol. 2007 Dec;17(6):436-43 [17681474.001]
  • [Cites] Semin Cancer Biol. 2007 Dec;17(6):413-21 [17881247.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1132-7 [11137218.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Immunogenetics. 2001 Oct;53(8):617-25 [11797094.001]
  • [Cites] J Pathol. 2002 Mar;196(3):266-74 [11857488.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1191-6 [12552087.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):512-8 [10225437.001]
  • (PMID = 18498645.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC2429914
  •  go-up   go-down


56. O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG: An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol; 2005 Aug;29(8):1034-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
  • Ovarian serous carcinoma (OSC) is the most common ovarian epithelial malignancy.
  • Recently, a dualistic pathway of ovarian serous carcinogenesis has been proposed based on morphologic observations and molecular genetic analysis.
  • In this scheme, low-grade OSC arises in a stepwise fashion from a benign serous cystadenoma through a usual serous borderline tumor through a micropapillary variant of serous borderline tumor.
  • In contrast, the more common high-grade OSC arises de novo from the ovarian surface epithelium or the epithelium of cortical inclusion cysts with an as yet unrecognized precursor lesion.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cystadenoma, Serous / chemistry. Cystadenoma, Serous / pathology. Ki-67 Antigen / analysis. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / pathology. Peptide Fragments / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-kit / analysis. Receptor, ErbB-2 / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Female. Humans. Inhibitor of Apoptosis Proteins. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Osteopontin. Sialoglycoproteins / analysis. WT1 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006797.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / HER2-neu-derived peptide (654-662); 0 / Inhibitor of Apoptosis Proteins; 0 / Ki-67 Antigen; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Peptide Fragments; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 0 / Tumor Suppressor Protein p53; 0 / WT1 Proteins; 106441-73-0 / Osteopontin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


57. Rabban JT, Krasik E, Chen LM, Powell CB, Crawford B, Zaloudek CJ: Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol; 2009 Dec;33(12):1878-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Risk-reducing salpingo-oophorectomy (RRSO) significantly lowers the incidence of ovarian, tubal, peritoneal, and breast cancer in women who carry BRCA1 or BRCA2 germline mutations.
  • Recommended protocols to maximize tumor detection emphasize the role of thinly slicing the tubes and ovaries and embedding the entire specimen for microscopic examination.
  • Clinically occult carcinoma ranging in size from 1 to 13 mm was initially detected in 11 of 102 women (5 in tubal fimbriae only, 1 in tubal isthmus only, 2 in fimbriae and ovary, and 3 in ovary only).
  • No tubal carcinoma was identified in the level sections of any case originally classified as benign.
  • Clinical follow-up among women with benign RRSO findings revealed that 2 women subsequently developed peritoneal carcinomatosis at 22 and 62 months postoperatively.
  • Retrospective exhaustive multistep level sectioning of all remaining tubal and ovarian blocks from both these women confirmed the original benign diagnosis in 1 woman but in the other woman, the deepest levels of 1 ovarian block revealed a single 1-mm nodule of cancer at the base of an ovarian surface epithelial invagination.
  • This specimen was one of the first RRSO cases in our experience and on review of the original report, this ovary was not dissected into multiple slices along its short axis but was only bivalved along its long axis.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898224.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human
  •  go-up   go-down


58. Lee WA: Mucinous cystadenoma of the pancreas with predominant stroma creating a solid tumor. World J Surg Oncol; 2005 Sep 7;3:59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous cystadenoma of the pancreas with predominant stroma creating a solid tumor.
  • BACKGROUND: Mucinous cystic neoplasm (MCN) of the pancreas is basically cystic epithelial neoplasm, unilocular or multilocular, occurring almost exclusively in women.
  • The sectioned surface of the pancreas revealed a circumscribed, whitish gray ovoid firm mass with some cystic spaces.
  • The subepithelial stromal component was composed of cytologically bland looking spindle cells, which resembled ovarian stroma.
  • The stromal cells were reactive to CD 34, vimentin, progesterone receptor and calretinin.
  • CONCLUSION: This case of mucinous cystadenoma of the pancreas showed very interesting pathology: It was solid rather than cystic, and accompanied by abundant benign transitional epithelia, which was a very unusual and novel finding in the mucinous cystic neoplasm of the pancreas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):86-91 [10658914.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):31-42 [10721805.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):66-80 [10721808.001]
  • [Cites] Verh Dtsch Ges Pathol. 2001;85:219-28 [11894402.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(1):116-9 [12021906.001]
  • [Cites] Pathol Int. 1997 Nov;47(11):806-8 [9413043.001]
  • [Cites] Int J Gynecol Pathol. 1993 Apr;12(2):128-33 [8463036.001]
  • [Cites] Obstet Gynecol. 1979 Nov;54(5):660-3 [503400.001]
  • [Cites] Cancer. 1979 May;43(5):1830-9 [445369.001]
  • [Cites] Pathologica. 1989 Jul-Aug;81(1074):381-401 [2696922.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):148-52 [15354741.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Apr;19(4):467-70 [15012791.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):1-16 [9888699.001]
  • (PMID = 16146567.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1236970
  •  go-up   go-down


59. Stanwell P, Russell P, Carter J, Pather S, Heintze S, Mountford C: Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at three Tesla. Invest Radiol; 2008 Oct;43(10):745-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at three Tesla.
  • AIM: The purpose of this study was to determine the feasibility of acquiring in vivo proton magnetic resonance spectroscopy of ovarian lesions at a magnetic field strength of 3 Tesla (T).
  • The goal was to provide potentially diagnostic biochemical information that may aid in the characterization of ovarian neoplasms detected during clinical magnetic resonance imaging scanning.
  • METHODS: Fourteen patients referred to 2 gynecologic oncologic surgeons were examined in a whole-body 3.0 T clinical scanner using an 8-element phased-array surface coil.
  • Magnetic resonance spectral findings were correlated with the detailed pathology reports obtained after resection of each tumor.
  • RESULTS: Pathology revealed 7 patients with malignant surface epithelial-stromal tumors, 3 patients with germ cell tumors, 3 patients with benign serous cystadenomas, and 1 patient with a non-neoplastic endometrioma.
  • Resonances attributable to choline-containing compounds and Cr were recorded in all malignant tumors and some of the benign tumors.
  • When detected, a choline/Cr integral ratio of greater than 3 was found to indicate that a tumor was malignant in nature, whereas a choline/Cr integral ratio less than 1.5 was found to indicate that a tumor was benign in nature.
  • CONCLUSIONS: Spectroscopy of ovarian masses can be recorded at 3.0 T with acceptable spectral quality and good signal-to-noise ratio.
  • [MeSH-major] Magnetic Resonance Imaging / instrumentation. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18791417.001).
  • [ISSN] 1536-0210
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Lin CH, Liu FS, Ho ES: Transitional cell carcinoma of the ovary. Taiwan J Obstet Gynecol; 2006 Sep;45(3):268-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the ovary.
  • OBJECTIVE: Transitional cell carcinoma (TCC) of the ovary is a rare, recently recognized, subtype of ovarian surface epithelial cancer.
  • We present a case of TCC of the ovary, managed by staging operation and followed by postoperative chemotherapy with carboplatin and cyclophosphamide.
  • After surgery, the pathologic report of the left ovarian tumor was TCC, grade 2-3, stage IA.
  • CONCLUSION: TCC of the ovary is a rare subtype of epithelial ovarian cancer.
  • It differs from malignant Brenner tumor by the absence of a benign or borderline Brenner component.
  • Surgical resection is the primary therapeutic approach, and patient outcomes after chemotherapy are better than for other types of common epithelial ovarian cancers.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Hysterectomy. Ovarian Neoplasms / surgery. Ovariectomy


61. Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, Galinsky D, Linke RP, Ariel I, Levin M, Ben-Shachar I, Prus D: Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J Histochem Cytochem; 2010 Nov;58(11):1015-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis.
  • Serum amyloid A (SAA) is an acute phase protein which is expressed primarily in the liver as a part of the systemic response to various injuries and inflammatory stimuli; its expression in ovarian tumors has not been described.
  • Here, we investigated the expression of SAA in human benign and malignant ovarian epithelial tumors.
  • Non-radioactive in situ hybridization applied on ovarian paraffin tissue sections revealed mostly negative SAA mRNA expression in normal surface epithelium.
  • Expression was increased gradually as epithelial cells progressed through benign and borderline adenomas to primary and metastatic adenocarcinomas.
  • RT-PCR analysis confirmed the overexpression of the SAA1 and SAA4 genes in ovarian carcinomas compared with normal ovarian tissues.
  • In addition, strong expression of SAA mRNA and protein was found in the ovarian carcinoma cell line OVCAR-3.
  • Finally, patients with ovarian carcinoma had high SAA serum levels, which strongly correlated with high levels of CA-125 and C-reactive protein.
  • Enhanced expression of SAA in ovarian carcinomas may play a role in ovarian tumorigenesis and may have therapeutic application.
  • [MeSH-major] Carcinoma / genetics. Carcinoma / pathology. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Serum Amyloid A Protein / genetics. Serum Amyloid A Protein / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. C-Reactive Protein / metabolism. CA-125 Antigen / blood. Cell Line, Tumor. Female. Humans. Middle Aged. Neoplasm Metastasis. Ovary / cytology. Ovary / metabolism. Ovary / pathology. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1983 Nov;43(11):5379-89 [6604576.001]
  • [Cites] Ann Intern Med. 1979 Sep;91(3):383-90 [289303.001]
  • [Cites] Scand J Immunol. 1984 Mar;19(3):193-8 [6200925.001]
  • [Cites] Biochem Biophys Res Commun. 1991 May 15;176(3):1100-5 [2039494.001]
  • [Cites] DNA Cell Biol. 1991 Nov;10(9):651-61 [1755958.001]
  • [Cites] J Biol Chem. 1992 Feb 25;267(6):3862-7 [1740433.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3186-90 [8159722.001]
  • [Cites] Genomics. 1994 Jan 15;19(2):228-35 [8188253.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):203-9 [7516407.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):650-60 [8080047.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1184-90 [7636186.001]
  • [Cites] Lab Invest. 1998 May;78(5):535-9 [9605178.001]
  • [Cites] J Histochem Cytochem. 1998 Dec;46(12):1377-84 [9815279.001]
  • [Cites] J Rheumatol. 1999 Apr;26(4):785-90 [10229397.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Eur J Immunol. 2005 Mar;35(3):718-26 [15724247.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 13;330(3):989-98 [15809093.001]
  • [Cites] Proteomics. 2005 Sep;5(14):3790-7 [16121334.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1361-9 [16211233.001]
  • [Cites] J Histochem Cytochem. 2006 Jan;54(1):63-73 [16116035.001]
  • [Cites] Arthritis Rheum. 2006 Jan;54(1):105-14 [16385502.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 9;247(1-2):4-21 [16297528.001]
  • [Cites] J Immunol. 2006 Oct 15;177(8):5585-94 [17015746.001]
  • [Cites] Biomed Environ Sci. 2007 Feb;20(1):33-40 [17458139.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):995-1005 [18195328.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Apr 4;368(2):368-73 [18237545.001]
  • [Cites] FEBS Lett. 2008 Mar 5;582(5):579-85 [18243142.001]
  • [Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):985-95 [18028381.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2199-208 [19307507.001]
  • [Cites] Br J Cancer. 2009 Jul 21;101(2):335-41 [19536090.001]
  • [Cites] Cancer. 2010 Feb 15;116(4):843-51 [20041483.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 Jul;136(7):1079-88 [20082099.001]
  • [Cites] Eur Urol. 2010 May;57(5):859-66 [19747761.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):794-7 [3734116.001]
  • [Cites] Curr Opin Hematol. 2000 Jan;7(1):64-9 [10608507.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Feb 16;268(2):405-8 [10679217.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):497-502 [11304683.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1224-9 [11830469.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] J Histochem Cytochem. 1984 Mar;32(3):322-8 [6363521.001]
  • (PMID = 20713982.001).
  • [ISSN] 1551-5044
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Serum Amyloid A Protein; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ PMC2958134
  •  go-up   go-down


62. Temkin S, Nacharaju VL, Hellman M, Lee YC, Abulafia O: Type 2 11beta-hydroxysteroid dehydrogenase activity in human ovarian cancer. Steroids; 2006 Nov;71(11-12):1019-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type 2 11beta-hydroxysteroid dehydrogenase activity in human ovarian cancer.
  • In the ovary cortisol-cortisone inter-conversion is catalyzed by the enzyme 11beta-hydroxysteroid dehydrogenase (11beta-HSD).
  • Its role in carcinomas of human ovary is unknown.
  • The majority of ovarian cancers are derived from ovarian surface epithelium and the inflammation caused by successive ovulation seems to a play a role in the development of cancer.
  • Cortisol is known to act as anti-inflammatory agent and its metabolism by type 1 and type 11beta-HSD may control the inflammatory action by cortisol in ovary.
  • We undertook this study to investigate type 2 11beta-HSD activity which functions exclusively oxidative direction, in normal ovarian tissue compared to ovarian epithelial cancer.
  • Ovarian tissue was obtained from patients undergoing hysterectomy for both benign and malignant disease.
  • Mean type 2 enzyme activity was 0.87 +/- 1.65 pmol/min g tissue in normal ovarian tissue versus a mean enzyme activity of 2.96 +/- 1.37 pmol/mim g tissue in from cancer specimens.
  • Type 2 1beta-HSD activity in ovarian cancer specimens was significantly higher than enzyme activity measured in normal post-menopausal ovarian tissue.
  • Decreased cortisol levels due type 2 1beta-HSD activity may play a role neoplastic transformation as well as tumor proliferation in ovarian cancer by eliminating anti-inflammatory action of cortisol.
  • [MeSH-major] 11-beta-Hydroxysteroid Dehydrogenase Type 2 / metabolism. Ovarian Neoplasms / enzymology
  • [MeSH-minor] Aged. Female. Humans. Isoenzymes / metabolism. Menopause. Middle Aged. Ovary / enzymology. Ovary / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17028049.001).
  • [ISSN] 0039-128X
  • [Journal-full-title] Steroids
  • [ISO-abbreviation] Steroids
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 1.1.1.146 / 11-beta-Hydroxysteroid Dehydrogenase Type 2
  •  go-up   go-down


63. Lewis MR, Deavers MT, Silva EG, Malpica A: Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol; 2006 Feb;30(2):177-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge.
  • Ovarian involvement by metastatic colorectal adenocarcinoma, although not an uncommon occurrence, remains a diagnostic challenge.
  • The gross and histologic features of such metastases overlap those of primary ovarian epithelial neoplasms such as endometrioid or mucinous adenocarcinoma.
  • The clinical and pathologic features of 86 cases of metastatic colorectal adenocarcinoma involving the ovary were reviewed.
  • In 23 cases, an ovarian mass was the first manifestation of the disease.
  • Ovarian involvement was bilateral in 49 cases and unilateral in 33 (including 20 cases in which the only involved ovary measured at least 10 cm in greatest dimension).
  • Many involved ovaries featured smooth capsules without gross evidence of surface involvement by tumor.
  • In 23 cases, foci with a benign or low malignant potential appearance were seen.
  • In 9 of the cases, an ovarian primary was diagnosed or favored initially, and 5 of these cases were initially treated as ovarian primaries.
  • Metastatic colorectal adenocarcinoma should be considered in the differential diagnosis of an ovarian mass, even if the mass is large and unilateral or in a young patient, to secure proper treatment of these patients.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434891.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


64. Zhai QJ, Ozcan A, Hamilton C, Shen SS, Coffey D, Krishnan B, Truong LD: PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: A comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol; 2010 Jul;18(4):323-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although PAX-2 is shown to be a sensitive marker for tumors derived from these organs, but whether it is specific, that is, whether other tumor types also express PAX-2, has not been systematically evaluated in either primary or metastatic tumors.
  • Among the non-neoplastic tissue, PAX-2 was expressed in glomerular parietal epithelial cells, renal collecting duct cells, atrophic renal tubular cells, epithelial cells of ovarian surface, fallopian tube, endocervix, endometrium, seminal vesicle, and lymphocytes.
  • Among the primary neoplasms, PAX-2 was noted in 104/122 (85%) of renal cell carcinoma, 31/95 carcinomas of Müllerian origin, 17/17 (100%) lymphomas, 4/4 (100%) nephrogenic adenomas, and 1/16 (6%) benign parathyroid tumors, but was negative in 477 other tumors.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216401.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor
  •  go-up   go-down


65. Zagorianakou N, Stefanou D, Makrydimas G, Zagorianakou P, Briasoulis E, Karavasilis V, Pavlidis N, Agnantis NJ: Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors. Histol Histopathol; 2006 04;21(4):341-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
  • This study examined the immunohistochemical expression of MTs in benign, borderline and malignant tumors of ovarian surface epithelium and the possible correlations with clinicopathological parameters and survival.
  • A total of 87 cases with diagnosis of ovarian surface epithelial tumors were included.
  • Specifically, 21 cases of benign cystadenomas (11 serous and 10 mucinous), 14 borderline (low malignant potential tumors, 8 mucinous and 6 serous) and 52 cases of ovarian cancer were analysed.
  • Immunohistochemical expression of MT (cut-off level > 10% of tumor cells) was clearly associated with malignancy.
  • A statistically significant correlation was found between the expression of MT in cancer cases and benign tumors (p < 0.0001) and cancer cases and borderline tumors p = 0.003.
  • There was no correlation of MT overexpression with survival in the small number of ovarian carcinoma patients where it was analysed.
  • MT constitutes a marker that characterizes aggressiveness and a high malignant potential in ovarian epithelial tumors.
  • In diagnostic problems MT may help distinguish between benign, borderline and malignant tumors.
  • [MeSH-major] Carcinoma / chemistry. Metallothionein / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Differentiation / genetics. Cell Proliferation. Cystadenoma, Mucinous / chemistry. Cystadenoma, Mucinous / diagnosis. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / chemistry. Cystadenoma, Serous / diagnosis. Cystadenoma, Serous / pathology. Diagnosis, Differential. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / physiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437378.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; 9038-94-2 / Metallothionein
  •  go-up   go-down






Advertisement